SEARCH REQUEST FORM has been submitted to SCORE as a separate file, due to SCORE file size limitations.

INVENTOR SEARCH
(Compounds were redacted from inventor search due to SCORE file size limitations.)

=> d ibib abs l8 1-2

L8 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1042075 HCAPLUS Full-text
DOCUMENT NUMBER: 143:347207
TITLE: Preparation of RSV replication-inhibiting benzodiazepine derivatives for use in pharmaceutical compositions in combination with RSV fusion protein inhibitors
INVENTOR(S): Powell, Kenneth; Kelsey, Richard; Carter, Malcolm; Dowdell, Verity; Alber, Dagmar; Henderson, Elisa
PATENT ASSIGNEE(S): Arrow Therapeutics Limited, UK
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089771	A1	20050929	WO 2005-GB1029	20050318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005224159	A1	20050929	AU 2005-224159	20050318
CA 2557931	A1	20050929	CA 2005-2557931	20050318
EP 1727551	A1	20061206	EP 2005-728747	20050318
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1933841	A	20070321	CN 2005-80008920	20050318
BR 2005007652	A	20070710	BR 2005-7652	20050318
JP 2007529491	T	20071025	JP 2007-503412	20050318
MX 2006PA10709	A	20061116	MX 2006-PA10709	20060919
IN 2006CN03411	A	20070706	IN 2006-CN3411	20060919
KR 2007009630	A	20070118	KR 2006-721651	20061018
US 20070185096	A1	20070809	US 2007-593382	20070314

PRIORITY APPLN. INFO.: GB 2004-6279 A 20040319
WO 2005-GB1029 W 20050318
OTHER SOURCE(S): CASREACT 143:347207; MARPAT 143:347207
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to a pharmaceutical composition comprising pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the respiratory syncytial virus (RSV) fusion protein of formula I [X = H, (un)substituted alkyl; Y = hetero/aryl, alkyl, alkoxy, etc.; Z = CH2 and derivs.; R1 = H, CONH2 and derivs., CO2H and derivs., (un)substituted alkyl; R2 = H, NH2, alkenyl, etc.; R3 = H, alkenyl, CO2H, etc.; Q = 1,2-dihydrobenzotriazol-1-yl, 2,3-dihydroindazol-1-yl, etc.]; and (b) a benzodiazepine derivative of formula II [R1 = alkyl, hetero/aryl; R2 = H, alkyl; each R3 = independently halo, OH, alkyl, alkoxy, NH2, CN, etc.; n = 0-3; R4 = H, alkyl; X = CO, SO, SO2, CONH and derivs.; R5 = (un)substituted hetero/aryl, heterocyclyl] capable of inhibiting RSV replication; the composition provides an additive and synergistic therapeutic effect in treating or preventing an RSV infection. The invention is also related to the preparation of benzodiazepines II. Thus, reacting (S)-3-Amino-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one with 2-chloro-4-(morpholin-4-yl)benzoic acid gave (S)-III. The fractional inhibitory concentration (FIC) for benzodiazepine III in combination with benzimidazole IV = 0.3, demonstrating a synergistic interaction.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1042073 HCAPLUS Full-text

DOCUMENT NUMBER: 143:339599

TITLE: Pharmaceutical composition comprising a benzodiazepine derivative and an inhibit or of the RSV fusion protein

INVENTOR(S): Powell, Kenneth; Kelsey, Richard; Carter, Malcolm; Alber, Dagmar; Wilson, Lara; Henderson, Elisa; Chambers, Phil; Taylor, Debra; Tyms, Stan; Dowdell, Verity

PATENT ASSIGNEE(S): Arrow Therapeutics Limited, UK

SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089769	A1	20050929	WO 2005-GB1018	20050318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005224157	A1	20050929	AU 2005-224157	20050318
CA 2558112	A1	20050929	CA 2005-2558112	20050318
EP 1727550	A1	20061206	EP 2005-718061	20050318
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1933842	A	20070321	CN 2005-80008927	20050318

BR 2005007654	A	20070710	BR 2005-7654		20050318
JP 2007529489	T	20071025	JP 2007-503410		20050318
MX 2006PA10711	A	20061116	MX 2006-PA10711		20060919
IN 2006CN03430	A	20070706	IN 2006-CN3430		20060919
KR 2007009629	A	20070118	KR 2006-721650		20061018
US 20070142403	A1	20070621	US 2007-593666		20070312
PRIORITY APPLN. INFO.:			GB 2004-6282	A	20040319
			WO 2005-GB1018	W	20050318

OTHER SOURCE(S): MARPAT 143:339599

AB A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is highly active against RSV.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RESULTS FROM REGISTRY AND CAPLUS

Elected species compound was retrieved via the following Accession Numbers: 2007:253120, 2005:1042075, and 2005:1042074. All are included in the following search results; all exceeded priority date.)

```
=> d que stat l20
L9                STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  13

STEREO ATTRIBUTES: NONE
L11         8863 SEA FILE=REGISTRY SSS FUL L9
L12          962 SEA FILE=HCAPLUS ABB=ON  L11
L13           46 SEA FILE=HCAPLUS ABB=ON  L12 AND (RSV+ALL OR ?ASTHMA? OR
                  (?CHRONIC?(W)?OBSTR?(W)?PULM? OR ?LUNG?)(W)?DISEAS?)
L16            1 SEA FILE=REGISTRY ABB=ON  865471-08-5/RN
L17            3 SEA FILE=HCAPLUS ABB=ON  L16
L18           46 SEA FILE=HCAPLUS ABB=ON  L13 OR L17
L19           23 SEA FILE=HCAPLUS ABB=ON  L18 AND (PRD<20040319 OR PD<20040319)
L20           26 SEA FILE=HCAPLUS ABB=ON  L17 OR L19


=> d ibib abs hitstr l20 1-26

L20  ANSWER 1 OF 26  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2007:253120  HCAPLUS  Full-text
DOCUMENT NUMBER:          146:371914
TITLE:                    1,4-Benzodiazepines as Inhibitors of Respiratory
                          Syncytial Virus. The Identification of a Clinical
                          Candidate
AUTHOR(S):                Henderson, Elisa A.; Alber, Dagmar G.; Baxter, Robert
                          C.; Bithell, Sian K.; Budworth, Joanna; Carter,
                          Malcolm C.; Chubb, Ann; Cockerill, G. Stuart; Dowdell,
                          Verity C. L.; Fraser, Ian J.; Harris, Robert A.;
                          Keegan, Sally J.; Kelsey, Richard D.; Lumley, James
                          A.; Stables, Jeremy N.; Weerasekera, Natasha; Wilson,
                          Lara J.; Powell, Kenneth L.
CORPORATE SOURCE:         Arrow Therapeutics, Britannia House, London, SE1 1DA,
                          UK
SOURCE:                   Journal of Medicinal Chemistry (2007), 50(7),
                          1685-1692
```

CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:371914

AB Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower respiratory tract infections worldwide and is increasingly being recognized as representing a serious threat to patient groups with poorly functioning or immature immune systems. Racemic 1,4-benzodiazepines show potent anti-RSV activity in vitro. Anti-RSV evaluation of 3-position R- and S-benzodiazepine enantiomers and subsequent optimization of this series resulted in selection of a clin. candidate. Antiviral activity was found to reside mainly in the S-enantiomer, and the R-enantiomers were consistently less active against RSV. Analogs of 1,4-(S)-benzodiazepine were synthesized as part of the lead optimization program at Arrow and tested in the XTT assay. From this exercise, (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]- diazepin-3-yl)-urea, 17b (RSV-604) was identified as a clin. candidate, exhibiting potent anti-RSV activity in the XTT assay, which was confirmed in secondary assays. Compound 17b also possessed a good pharmacokinetic profile and has now progressed into the clinic.

IT 865471-08-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzodiazepines as inhibitors of respiratory syncytial virus)

RN 865471-08-5 HCAPLUS

CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-fluoro-2-(1-piperidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1225554 HCAPLUS Full-text
DOCUMENT NUMBER: 145:500161
TITLE: γ-Secretase inhibitors for promoting angiogenesis
INVENTOR(S): Hellstrom, Mats; Karlsson, Linda; Wallgard, Elisabeth
PATENT ASSIGNEE(S): Swed.
SOURCE: U.S. Pat. Appl. Publ., 29pp., Cont.-in-part of Appl. No. PCT/SE2004/001146.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060264380	A1	20061123	US 2006-306973	20060118 <--
WO 2005008250	A1	20050127	WO 2004-SE1146	20040721 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:		
SE 2003-2111	A	20030721 <--
US 2003-488345P	P	20030721 <--
WO 2004-SE1146	A2	20040721

AB Angiogenesis may be initiated or increased through the use of γ-secretase inhibitors. The γ-secretase inhibitor can be a dipeptide class, sulfonamide class, transition state mimic class, benzodiazepine class, or benzocaprolactam class γ-secretase inhibitor. Methods for initiating and increasing angiogenesis are used for disease prevention and treatment as well as for generating research models. Thus, cells treated with 0.16 μM of a sulfonamide-class γ-secretase inhibitor 1-(S)-endo-N-[1,3,3]-trimethylbicyclo[2.2.1]hept-2-yl-4-fluorophenyl sulfonamide (I) showed a 100% increase in length (280 μm ± 23 μm vs. 120 μm ± 15 μm for the control cells), demonstrating promotion of angiogenesis. When coadministered with VEGF, a concentration of 20 μM I resulted in an average sprout length of 480 μm ± 19 μm, whereas control cells treated with VEGF alone had an average length of 370 μm ± 25 μm. More titrns. might reveal effects of a sulfonamide group compound at lower concns. as well.

IT 646036-32-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(γ-secretase inhibitors for promoting angiogenesis and their therapeutic uses)

RN 646036-32-0 HCAPLUS

CN Benzeneacetamide, N-[(1S)-2-[[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-α-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 3 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:100738 HCAPLUS Full-text
DOCUMENT NUMBER: 144:198849
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20060024365	A1	20060202	US 2005-134633	20050519	<--
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805	
IN 193042	A1	20040626			
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805	
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122	
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122	
US 20040096499	A1	20040520	US 2003-630446	20030729	<--
PRIORITY APPLN. INFO.:			IN 2002-MU697 A	20020805	<--
			IN 2002-MU699 A	20020805	<--
			IN 2003-MU80 A	20030122	<--
			IN 2003-MU82 A	20030122	<--
			US 2003-630446 A2	20030729	<--

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

IT 103420-77-5, Devazepide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

RN 103420-77-5 HCAPLUS
CN 1H-Indole-2-carboxamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L20 ANSWER 4 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1042075 HCAPLUS Full-text
DOCUMENT NUMBER: 143:347207
TITLE: Preparation of RSV replication-inhibiting benzodiazepine derivatives for use in pharmaceutical compositions in combination with RSV fusion protein inhibitors
INVENTOR(S): Powell, Kenneth; Kelsey, Richard; Carter, Malcolm; Dowdell, Verity; Alber, Dagmar; Henderson, Elisa
PATENT ASSIGNEE(S): Arrow Therapeutics Limited, UK
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089771	A1	20050929	WO 2005-GB1029	20050318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005224159	A1	20050929	AU 2005-224159	20050318
CA 2557931	A1	20050929	CA 2005-2557931	20050318
EP 1727551	A1	20061206	EP 2005-728747	20050318
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1933841	A	20070321	CN 2005-80008920	20050318
BR 2005007652	A	20070710	BR 2005-7652	20050318
JP 2007529491	T	20071025	JP 2007-503412	20050318
MX 2006PA10709	A	20061116	MX 2006-PA10709	20060919
IN 2006CN03411	A	20070706	IN 2006-CN3411	20060919
KR 2007009630	A	20070118	KR 2006-721651	20061018
US 20070185096	A1	20070809	US 2007-593382	20070314

PRIORITY APPLN. INFO.:	GB 2004-6279	A	20040319
	WO 2005-GB1029	W	20050318

OTHER SOURCE(S): CASREACT 143:347207; MARPAT 143:347207
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to a pharmaceutical composition comprising pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the respiratory syncytial virus (RSV) fusion protein of formula I [X = H, (un)substituted alkyl; Y = hetero/aryl, alkyl, alkoxy, etc.; Z = CH2 and derivs.; R1 = H, CONH2 and derivs., CO2H and derivs., (un)substituted alkyl; R2 = H, NH2, alkenyl, etc.; R3 = H, alkenyl, CO2H, etc.; Q = 1,2-dihydrobenzotriazol-1-yl, 2,3-dihydroindazol-1-yl, etc.]; and (b) a benzodiazepine derivative of formula II [R1 = alkyl, hetero/aryl; R2 = H,

alkyl; each R3 = independently halo, OH, alkyl, alkoxy, NH2, CN, etc.; n = 0-3; R4 = H, alkyl; X = CO, SO, SO2, CONH and derivs.; R5 = (un)substituted hetero/aryl, heterocyclyl] capable of inhibiting RSV replication; the composition provides an additive and synergistic therapeutic effect in treating or preventing an RSV infection. The invention is also related to the preparation of benzodiazepines II. Thus, reacting (S)-3-Amino-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one with 2-chloro-4-(morpholin-4-yl)benzoic acid gave (S)-III. The fractional inhibitory concentration (FIC) for benzodiazepine III in combination with benzimidazole IV = 0.3, demonstrating a synergistic interaction.

IT 865471-08-5P, (S)-4-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(piperidin-1-yl)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of RSV replication-inhibiting benzodiazepine derivs. for use in pharmaceutical compns. in combination with RSV fusion protein inhibitors)

RN 865471-08-5 HCAPLUS

CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-fluoro-2-(1-piperidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1042074 HCAPLUS Full-text

DOCUMENT NUMBER: 143:326400

TITLE: Benzodiazepinones for treating or preventing human respiratory syncytial viral infection and other diseases

INVENTOR(S): Dowdell, Verity; Carter, Malcolm; Alber, Dagmar; Henderson, Elisa

PATENT ASSIGNEE(S): Arrow Therapeutics Limited, UK; Kelsey, Richard

SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089770	A1	20050929	WO 2005-GB1023	20050318

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2005224158	A1	20050929	AU 2005-224158		20050318
CA 2557929	A1	20050929	CA 2005-2557929		20050318
EP 1740185	A1	20070110	EP 2005-718065		20050318
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 1929848	A	20070314	CN 2005-80008070		20050318
BR 2005008968	A	20070821	BR 2005-8968		20050318
JP 2007529490	T	20071025	JP 2007-503411		20050318
MX 2006PA10710	A	20070308	MX 2006-PA10710		20060919
IN 2006CN03425	A	20070706	IN 2006-CN3425		20060919
KR 2007017357	A	20070209	KR 2006-721652		20061018
US 20080139536	A1	20080612	US 2007-593667		20070802
PRIORITY APPLN. INFO.:			GB 2004-6280	A	20040319
			WO 2005-GB1023	W	20050318

OTHER SOURCE(S): MARPAT 143:326400

GI



AB Use is claimed of benzodiazepinones (shown as I; variables defined below; e.g. 6-(4-methylpiperazin-1-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide (shown as II)) or an N-oxide thereof or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or preventing an human respiratory syncytial viral (RSV) infection. RSV antiviral activities for 52 examples of I are tabulated. For I: R1 = C1-6 alkyl, aryl or heteroaryl; R2 = H or C1-6 alkyl; each R3 = halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6alkyl)amino, nitro, cyano, CO2R', CONR'R'', NHCOR', S(O)R', S(O)2R', NHS(O)2R', S(O)NR'R'' or S(O)2NR'R'', wherein each R' and R'' = H or C1-6 alkyl; n = 0 to 3; R4 = H or C1-6 alkyl. X = CO, CONR', S(O) or S(O)2, wherein R' is H or a C1-C6 alkyl group; and R5 = a heteroaryl or heterocyclyl group which is substituted by a C1-C6 hydroxyalkyl group or a -(C1-C4 alkyl)-X1-(C1-C4 alkyl)-X2-(C1-C4 alkyl) group, wherein X1 = -O-, -S- or -NR', wherein R' = H or a C1-C4 alkyl group

and X2 = CO, SO or SO2, or R55 = -A1-Y-A2, wherein A1 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group; Y = a direct bond or a C1-C4 alkylene, SO2, CO, -O-, -S- or -NR' moiety, wherein R' is a C1-C6 alkyl group; and A2 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group. Although the methods of preparation are not claimed, .apprx.50 example prepns. are included. For example, II was prepared in MeCN using microwave heating and Et3N from N-methylpiperazine and 6-chloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide, which was prepared in DMF from 3-amino-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one and 6-chloronicotinic acid using O-benzotriazol-1-yl-N,N,N',N'- tetramethyluronium hexafluorophosphate and Et3N.

IT 865471-08-5P, (S)-4-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(piperidin-1-yl)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; benzodiazepinones for treating or preventing human respiratory syncytial viral infection and other diseases)

RN 865471-08-5 HCAPLUS

CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-fluoro-2-(1-piperidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2005:823578 HCAPLUS Full-text
DOCUMENT NUMBER:	143:229872
TITLE:	Preparation of aminopyri(mi)dinecarboxamide CB2 modulators for use in combination with PDE4 inhibitors for treating pain, immune, inflammatory and rheumatic diseases
INVENTOR(S):	Green, Richard Howard; Brown, Andrew James; Connor, Helen Elizabeth; Eatherton, Andrew John; Giblin, Gerard Martin Paul; Jandu, Karamjit Singh; Knowles, Richard Graham; Mitchell, William Leonard; Naylor, Alan; O'Shaughnessy, Celestine Theresa; Palombi, Giovanni; Rawlings, Derek Anthony; Slingsby, Brian Peter; Tralau-Stewart, Catherine Jane; Whittington, Andrew Richard; Williamson, Richard Alexander
PATENT ASSIGNEE(S):	Glaxo Group Limited, UK; Doughty, Jennifer Margaret
SOURCE:	PCT Int. Appl., 192 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074939	A1	20050818	WO 2005-GB348	20050201 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1732561	A1	20061220	EP 2005-702088	20050201 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007520538	T	20070726	JP 2006-551906	20050201 <--
US 20080132505	A1	20080605	US 2006-597527	20061102 <--
PRIORITY APPLN. INFO.:			GB 2004-2355 A	20040203 <--
			WO 2005-GB348 W	20050201

OTHER SOURCE(S): CASREACT 143:229872; MARPAT 143:229872

GI



I



II

AB The invention is related to combination of one or more CB2 modulators of formula I [X = CH, N; Y = (un)substituted Ph; R1 = H, cyclo/alkyl, (un)substituted haloalkyl; R2 = C(R7)2R3; R3 = (un)substituted non-aromatic heterocyclyl, cycloalk(en)yl, 5-6 membered aromatic heterocyclyl, etc.; R4 = H, COMe, SO2Me, cyclo/alkyl, (un)substituted haloalkyl; R6 = Me, Cl, CHmFn; n = 1-3; m = 0-2; (n + m) = 3; R7 = H, alkyl; when X = CH, R6 = Cl, or (un)substituted alkyl and R10 = H, or R10 = Cl, or (un)substituted alkyl and R10 = H; and their pharmaceutically acceptable salts] and one or more PDE4 inhibitors useful for treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4, such as an immune disorder, an inflammatory disorder, pain, rheumatoid. The invention is also related to the preparation of CB2 modulators I. For example, reacting cyclobutylamine with 6-(2,3-dichlorophenylamino)-4-trifluoromethylnicotinic acid (preparation given) gave II in 81% yield. Selected I had EC50 values of

>300 nM but <1000 nM and efficacy value of >50% at the cloned human cannabinoid CB2 receptor. Three formulations are given.

IT 245329-99-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PDE4 inhibitor, combination therapy agent; preparation of aminopyri(mi)dinecarboxamide CB2 modulators for use in combination with PDE4 inhibitors for treating pain, immune, inflammatory and rheumatic diseases)

RN 245329-99-1 HCAPLUS

CN 4-Pyridinecarboxamide, N-(3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:405366 HCAPLUS Full-text
DOCUMENT NUMBER: 142:441879
TITLE: Method and compositions for the treatment or prevention of respiratory inflammation using a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor
INVENTOR(S): Smith, Walter G.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041864	A2	20050512	WO 2004-US34685	20041021 <--
WO 2005041864	A3	20060518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050187278	A1	20050825	US 2004-927198	20040826 <--
CA 2542277	A1	20050512	CA 2004-2542277	20041021 <--
EP 1691797	A2	20060823	EP 2004-795797	20041021 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

BR 2004015753	A	20061219	BR 2004-15753		20041021	<--
JP 2007509154	T	20070412	JP 2006-536743		20041021	<--
MX 2006PA04499	A	20060627	MX 2006-PA4499		20060421	<--
PRIORITY APPLN. INFO.:			US 2003-513099P	P	20031021	<--
			US 2003-498529P	P	20030828	<--
			WO 2004-US34685	W	20041021	

AB A method is described for the prevention and/or treatment of respiratory inflammation, and in particular asthma and COPD, in a subject in need of such prevention or treatment, the method comprising administering to the subject a cyclooxygenase 2 inhibitor in combination with a phosphodiesterase 4 inhibitor. Also described are therapeutic and pharmaceutical comps. and kits that are useful in the invention. Preparation of celecoxib and of roflumilast is described, as is the production of a composition containing these two compds.

IT 245329-99-1, CI 1018
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CI 1018; COX2 inhibitor-PDE4 inhibitor combination for treatment and prevention of respiratory inflammation)

RN 245329-99-1 HCAPLUS

CN 4-Pyridinecarboxamide, N-(3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)- (CA INDEX NAME)



L20 ANSWER 8 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2005:136543 HCAPLUS Full-text
DOCUMENT NUMBER:	142:246142
TITLE:	Medicaments comprising PDE IV inhibitors and an anticholinergic agent for treating respiratory disorders
INVENTOR(S):	Germeyer, Sabine; Meade, Christopher John Montague; Meissner, Helmut; Morschhaeuser, Gerd; Pairet, Michel; Pestel, Sabine; Pieper, Michael P.; Pohl, Gerald; Reichl, Richard; Speck, Georg
PATENT ASSIGNEE(S):	Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE:	PCT Int. Appl., 41 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013967	A1	20050217	WO 2004-EP8003	20040723 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20050043343	A1	20050224	US 2004-891562		20040715 <--
CA 2533786	A1	20050217	CA 2004-2533786		20040723 <--
EP 1651208	A1	20060503	EP 2004-741118		20040723 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
JP 2007500148	T	20070111	JP 2006-521453		20040723 <--
PRIORITY APPLN. INFO.:			EP 2003-17039	A	20030728 <--
			US 2003-508119P	P	20031002 <--
			WO 2004-EP8003	W	20040723

OTHER SOURCE(S): MARPAT 142:246142

AB The present invention relates to pharmaceutical compns. based on PDE IV inhibitors and salts of a novel anticholinergic, processes for preparing them and their use in the treatment of respiratory complaints. For example, scopine 9-methylfluorene-9-carboxylate methobromide was prepared and formulated into inhalable powder containing the drug 80 μg, AWD-12-281 200 μg, and lactose 12220 μg per capsule.

IT 179024-48-7, PD 168787
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalable compns. comprising anticholinergic agent and PDE IV inhibitors for treating respiratory disorders)

RN 179024-48-7 HCAPLUS

CN 4-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 9 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:995964 HCAPLUS Full-text
DOCUMENT NUMBER:	141:424183
TITLE:	Preparation of 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases
INVENTOR(S):	Tung, Jay S.; Garofalo, Albert W.; Pleiss, Michael A.; Wu, Jing; Wone, David W. G.; Guinn, Ashley C.; Dressen, Darren B.; Neitz, R. Jeffrey; Marugg, Jennifer; Neitzel, Martin
PATENT ASSIGNEE(S):	Elan Pharmaceuticals, Inc., USA
SOURCE:	PCT Int. Appl., 374 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098589	A1	20041118	WO 2004-US13219	20040430 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2524269	A1	20041118	CA 2004-2524269	20040430 <--
US 20050020659	A1	20050127	US 2004-837231	20040430 <--
US 7432379	B2	20081007		
EP 1633348	A1	20060315	EP 2004-750891	20040430 <--
EP 1633348	B1	20081008		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006526015	T	20061116	JP 2006-513431	20040430 <--
US 20060281733	A1	20061214	US 2005-555519	20051102 <--
US 7417152	B2	20080826		

PRIORITY APPLN. INFO.:			US 2003-467695P	P 20030502 <--
			US 2004-539546P	P 20040127 <--
			WO 2004-US13219	W 20040430

OTHER SOURCE(S): MARPAT 141:424183
GI



I



II



III

AB Disclosed are compds. I and II [Z1 = O, S, NH; Q = NR4R5, OH, alkyl, cycloalkyl, etc.; R1 = H, alkyl, aryl, etc.; R2, R3 = H, alkyl, aryl, etc.; R4, R5 = H, alkyl, alkoxy, cycloalkyl, etc.; or NR4R5 = (un)substituted heterocyclyl, heteroaryl; X = H, halo, alkyl, NO2, etc.; with provisos] that are bradykinin B1 receptor antagonists and are useful for treating diseases,

or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. The general procedures for synthesis of the compds. I and II were given. E.g., a multi-step synthesis (no characterization data given for the intermediates) of the amide III, was described. The compds. I and II were tested for potency and efficacy to inhibit the bradykinin B1 receptor in a cell-based fluorescent calcium-mobilization assay. Their potency was demonstrated by results of less than 50 μM. Certain of the compds. I and II exhibit increased potency and are also expected to exhibit increased duration of action. The pharmaceutical compns. comprising the title compds. are described and claimed.

IT 796035-13-3P 796036-07-2P 796036-09-4P
796036-10-7P 796036-12-9P 796036-14-1P
796036-17-4P 796036-18-5P 796036-43-6P
796036-44-7P 796036-45-8P 796036-46-9P
796036-59-4P 796036-60-7P 796036-61-8P
796036-62-9P 796036-64-1P 796036-65-2P
796036-66-3P 796036-67-4P 796036-68-5P
796036-69-6P 796036-71-0P 796036-73-2P
796036-74-3P 796036-75-4P 796036-95-8P
796036-96-9P 796036-97-0P 796037-13-3P
796037-16-6P 796037-17-7P 796037-23-5P
796037-26-8P 796037-98-4P 796037-99-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amides as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases)

RN 796035-19-3 HCAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methyl-1-(2-pyridinyl)- (CA INDEX NAME)



RN 796036-07-2 HCAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-09-4 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-10-7 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-12-9 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-14-1 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-[(2-chlorobenzoyl)amino]-N-(5-cyclohexyl-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-17-4 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-5-[(2-chlorobenzoyl)amino]-N-[7-chloro-5-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 796036-18-5 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-5-[(2-chlorobenzoyl)amino]-N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-43-6 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-[(2-chlorobenzoyl)amino]-N-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 796036-44-7 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-5-[(2-chlorobenzoyl)amino]-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 796036-45-8 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-5-[(2-chlorobenzoyl)amino]-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 796036-46-9 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-59-4 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-[(2-methyl-1-oxopropyl)amino]- (CA INDEX NAME)



RN 796036-60-7 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-[(2-fluorobenzoyl)amino]- (CA INDEX NAME)



RN 796036-61-8 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-(acetylamino)-4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-62-9 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-(benzoylamino)-4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-64-1 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-(benzoylamino)-4-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-65-2 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-

benzodiazepin-3-yl)-5-[(2-methylbenzoyl)amino]- (CA INDEX NAME)



RN 796036-66-3 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-[(3,5-dichlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-67-4 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-[(4-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-68-5 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-[(2-chlorobenzoyl)amino]-N-(1-ethyl-

2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-69-6 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-[(3-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-71-0 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-5-[(3-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 796036-73-2 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-fluoro- (CA INDEX NAME)



RN 796036-74-3 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-[(2-fluorobenzoyl)amino]- (CA INDEX NAME)



RN 796036-75-4 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N-methyl- (CA INDEX NAME)



RN 796036-95-8 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[5-(3-azabicyclo[3.2.2]non-3-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-chloro-5-[(2-

chlorobenzoyl)amino]- (CA INDEX NAME)



RN 796036-96-9 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[5-(3-azabicyclo[3.2.2]non-3-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-bromo-5-[(2-chlorobenzoyl)amino]- (CA INDEX NAME)



RN 796036-97-0 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-5-[(2-chlorobenzoyl)amino]-N-[2,3-dihydro-2-oxo-5-(2-phenylethyl)-1-propyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 796037-13-3 HCAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-chloro-N-(1-ethyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-[(2-methylbenzoyl)amino]- (CA INDEX NAME)



RN 796037-16-6 HCAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-1-methyl- (CA INDEX NAME)



RN 796037-17-7 HCAPLUS

CN 1H-Pyrazole-5-carboxamide, 3-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-1-methyl- (CA INDEX NAME)



RN 796037-23-5 HCAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-

5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methyl- (CA INDEX NAME)



RN 796037-26-8 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-1-methyl- (CA INDEX NAME)



RN 796037-98-4 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(2-chlorobenzoyl)amino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-1-phenyl- (CA INDEX NAME)



RN 796037-99-5 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-[(2-chlorobenzoyl)amino]-N-(2,3-

dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-1-phenyl- (CA INDEX NAME)



IT 894-77-9, 3-Amino-7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one 103343-47-1, 3-Amino-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 103343-65-3, (R)-3-Amino-1-methyl-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 103421-61-0, 3-Amino-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one 106849-47-2, (1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester 108895-98-3 145878-32-6, 3-Amino-1-ethyl-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 155452-87-2, (7-Chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)carbamic acid phenylmethyl ester 209985-28-4, [7-Chloro-5-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]carbamic acid phenylmethyl ester 253135-95-4, (S)-3-Amino-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 308243-63-2, 3-Amino-7-chloro-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one 788814-76-6, 3-Amino-5-cyclohexyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 796038-21-6, (R)-3-Amino-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 796038-27-2, 1-Methyl-3-methylamino-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amides as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases)

RN 894-77-9 HCAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-7-chloro-1,3-dihydro-5-phenyl- (CA INDEX NAME)



RN 103343-47-1 HCAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-5-phenyl- (CA INDEX NAME)



RN 103343-65-3 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-1-methyl-5-phenyl-, (3R)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 103421-61-0 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-1-methyl-5-phenyl- (CA
INDEX NAME)



RN 106849-47-2 HCAPLUS
CN Carbamic acid, (2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-
yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 108895-98-3 HCAPLUS
CN Carbamic acid, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-,

phenylmethyl ester (CA INDEX NAME)



RN 145878-32-6 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-ethyl-1,3-dihydro-5-phenyl- (CA INDEX NAME)



RN 155452-87-2 HCAPLUS
CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 209985-28-4 HCAPLUS
CN Carbamic acid, [7-chloro-5-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 253135-95-4 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-5-phenyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 308243-63-2 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-7-chloro-5-(2-chlorophenyl)-1,3-dihydro- (CA INDEX NAME)



RN 788814-76-6 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-5-cyclohexyl-1,3-dihydro- (CA INDEX NAME)



RN 796038-21-6 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-5-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 796038-27-2 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-methyl-3-(methylamino)-5-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 10 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:549690 HCAPLUS Full-text
DOCUMENT NUMBER: 141:94329
TITLE: Inhalant compositions containing neutrophil elastase inhibitors
INVENTOR(S): Hagio, Tetsuya; Sekioka, Tomohiko; Nishimura, Hidekatsu
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 39 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004189659	A	20040708	JP 2002-358630	20021210 <--
PRIORITY APPLN. INFO.:			JP 2002-358630	20021210 <--

OTHER SOURCE(S): MARPAT 141:94329
GI



I

AB The invention relates to an inhalant composition containing a neutrophil elastase inhibitor consisting of a five-membered heterocyclic compound I, (one of X or Y is -N= and the other is NH, NR2, O, or S; α or β is double or single bond depending on X and Y; R1, R2 = alkyl, alkenyl, haloalkyl, haloalkenyl, alkynyl, halogen, cyano, nitro, amino, aminoalkyl, dialkylamino, etc; Z = amino-containing group) for treatment of respiratory tract disease. An inhalant composition containing 2-[5-amino-6-oxo-2-phenyl-1,6-dihydro-1-pyrimidinyl]-N-[1-[[5-(tert-butyl)- 1,3,4-oxadiazol-2-yl]carbonyl]-2-methylpropyl]acetamide was formulated, and applied to neutrophil elastase-induced acute lung hemorrhage model hamsters.

IT 208845-74-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalant compns. containing neutrophil elastase inhibitors consisting of five-membered heterocyclic compds.)
RN 208845-74-3 HCAPLUS
CN 1H-1,4-Benzodiazepine-1-acetamide, 3-amino-2,3-dihydro-N-[(1S)-2-methyl-1-[[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]carbonyl]propyl]-2-oxo-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:546396 HCAPLUS Full-text
DOCUMENT NUMBER: 141:106280
TITLE: Preparation of substituted N-phenylsulfonamide derivatives for use in pharmaceutical compositions as bradykinin antagonists
INVENTOR(S): Grant, Francine S.; Dappen, Michael S.; Xu, Ying-i; Bartulis, Sarah; Holcomb, Ryan C.; Kasar, Ramesh A.; Pleiss, Michael A.; Thorsett, Eugene D.; Ye, Michael; Konradi, Andrei W.
PATENT ASSIGNEE(S): Elan Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056319	A2	20040708	WO 2003-US40745	20031218 <--
WO 2004056319	A3	20040902		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509881	A1	20040708	CA 2003-2509881	20031218 <--
AU 2003299757	A1	20040714	AU 2003-299757	20031218 <--

EP 1572678 A2 20050914 EP 2003-800037 20031218 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006516132 T 20060622 JP 2004-562344 20031218 <--
US 20070093485 A1 20070426 US 2005-527384 20050309 <--
PRIORITY APPLN. INFO.: US 2002-435123P P 20021219 <--
WO 2003-US40745 W 20031218 <--
OTHER SOURCE(S): MARPAT 141:106280
GI



I

II

AB N-phenylsulfonamides, such as I [R = H, NH2, NO2, CN, OH, alkyl, substituted amino, alkoxy, aryl, heteroaryl, heterocyclyl, acyl, halogen, carboxy, carboxamide, etc.; R1 = aryl, heteroaryl, heterocyclyl; R2 = H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; R3, R3' = H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl; X = C2-3-alkylene, -alkynylene; n = 0-3], were prepared for therapeutic use as bradykinin antagonists. These sulfonamides were claimed for use in the treatment of adverse symptoms mediated at least in part by the presence or secretion of bradykinin, such as pain, inflammation, bronchoconstriction, edema, cerebral edema, hyperalgesia, hyperthermia, burns, perioperative pain, migraine, shock, central nervous system injury, asthma, rhinitis, premature labor, inflammatory arthritis, inflammatory bowel disease or neuropathic pain. Thus, sulfonamide II was prepared in four steps via an N-sulfonylation reaction 4-chloro-2,5-dimethylbenzenesulfonyl chloride with sodium 3-(2-aminophenyl)propionate and subsequent amidation reaction of the acid thus formed with 1-(R)-[1-amino-1-(pyrrolidin-1-ylcarbonyl)]-2-(4-pyridyl)ethane. The prepared sulfonamides were tested for potency and efficacy to inhibit the bradykinin B1 receptor in a cell-based fluorescent calcium-mobilization assay using IMR-90 human lung fibroblast cells.

IT 720001-56-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenylsulfonamides for use in pharmaceutical comps. as bradykinin antagonists)

RN 720001-56-9 HCAPLUS

CN Benzenepropanamide, 2-[[(4-chloro-2,5-dimethylphenyl)sulfonyl]ethylamino]-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



L20 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:467725 HCAPLUS Full-text
DOCUMENT NUMBER: 141:17651
TITLE: Phosphodiesterase IV and phosphodiesterase III/IV inhibitors for use in the treatment of cachexia
INVENTOR(S): Schmidt, Mathias
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004047817	A1	20040610	WO 2003-EP13313	20031126 <--
W: AE, AL, AU, BA, BR, CA, CN, CO, DZ, EC, EG, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2506949	A1	20040610	CA 2003-2506949	20031126 <--
AU 2003289898	A1	20040618	AU 2003-289898	20031126 <--
EP 1567136	A1	20050831	EP 2003-782232	20031126 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508996	T	20060316	JP 2004-554493	20031126 <--
US 20060079540	A1	20060413	US 2005-535815	20050520 <--
PRIORITY APPLN. INFO.:			EP 2002-26548 A	20021127 <--
			WO 2003-EP13313 W	20031126 <--

AB The invention discloses the use of a PDE IV or PDE III/IV inhibitor for the treatment of cachexia.

IT 179024-48-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase IV and phosphodiesterase III/IV inhibitors for treatment of cachexia)

RN 179024-48-7 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 13 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:464117 HCAPLUS Full-text
DOCUMENT NUMBER: 141:33566
TITLE: Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors
AUTHOR(S): Martin-Chouly, Corinne A. E.; Astier, Alexandra; Jacob, Claire; Pruniaux, Marie-Pierre; Bertrand, Claude; Lagente, Vincent
CORPORATE SOURCE: INSERM U456, Universite de Rennes 1, Rennes, 35043, Fr.
SOURCE: Life Sciences (2004), 75(7), 823-840
CODEN: LIFSAK; ISSN: 0024-3205
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Over-expression of matrix metalloproteinases by lung fibroblasts has been blamed for much of the tissue destruction associated with airway inflammation. Because cAMP is known to regulate fibroblast proliferation, as well as cytokine and extracellular matrix protein production, the current study was designed to evaluate the ability of three selective phosphodiesterase (PDE) type 4 inhibitors, rolipram, cilomilast and CI-1044, to inhibit extracellular matrix degradation Using zymog. and ELISA, we found that pro-MMP-2 release was enhanced following 24 h treatment of human lung fibroblast (MRC-5) with TGF-β1 (10 ng/mL) or TNF-α (10 ng/mL), whereas PMA (0.02 μM) had no effect. One hour of pre-incubation with PDE4 inhibitors (10 μM) induced an inhibition of TNF-α-stimulated pro-MMP-2 release. Zymog. and immunoblotting revealed that fibroblasts cultured with PMA or TNF-α released increased amts. of pro-MMP-1, whereas TGF-β1 had no effect. Incubation with CI-1044 or cilomilast significantly prevented the TNF-α increase in pro-MMP-1. These results suggest that PDE4 inhibitors are effective in inhibiting the pro-MMP-2 and pro-MMP-1 secretion induced by TNF-α and might underline a potential therapeutic benefit of selective PDE4 inhibitors in lung diseases associated with abnormal tissue remodelling.

IT 197894-84-1, CI-1044
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors and therapeutic potential)
RN 197894-84-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 14 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:267311 HCAPLUS Full-text
DOCUMENT NUMBER: 140:287417
TITLE: Preparation of aminobenzodiazepinones and pharmaceutical compositions containing them for use against respiratory syncytial virus
INVENTOR(S): Carter, Malcolm; Henderson, Elisa; Kelsey, Richard; Wilson, Lara; Chambers, Phil; Taylor, Debra; Tyms, Stan
PATENT ASSIGNEE(S): Arrow Therapeutics Limited, UK
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026843	A1	20040401	WO 2003-GB4050	20030922 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499322	A1	20040401	CA 2003-2499322	20030922 <--
AU 2003267587	A1	20040408	AU 2003-267587	20030922 <--
EP 1539716	A1	20050615	EP 2003-748279	20030922 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014595	A	20050809	BR 2003-14595	20030922 <--
CN 1694874	A	20051109	CN 2003-825190	20030922 <--
JP 2006503054	T	20060126	JP 2004-537305	20030922 <--
NZ 538870	A	20070427	NZ 2003-538870	20030922 <--
ZA 2005002001	A	20060628	ZA 2005-2001	20050309 <--
MX 2005PA02871	A	20051005	MX 2005-PA2871	20050315 <--
IN 2005CN00400	A	20070406	IN 2005-CN400	20050316 <--
NO 2005001908	A	20050419	NO 2005-1908	20050419 <--
US 20060040923	A1	20060223	US 2005-528250	20050621 <--
IN 2007CN04798	A	20080321	IN 2007-CN4798	20071026 <--

PRIORITY APPLN. INFO.: GB 2002-21923 A 20020920 <--
GB 2003-2078 A 20030129 <--
WO 2003-GB4050 W 20030922 <--
IN 2005-CN400 A3 20050316

OTHER SOURCE(S): MARPAT 140:287417

GI



I



II

AB Benzodiazepines (shown as I; variables defined below; e.g. II) and pharmaceutically acceptable salts thereof, are active against respiratory syncytial virus (RSV). For I: R1 = C1-6 alkyl, aryl or heteroaryl; R2 = H or C1-6 alkyl; each R3 = halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, -CO2RI, -CONRIRII, -NH-CO-RI, -S(O)RI, -S(O)2RI, -NH-S(O)2RI, -S(O)NRIRII or -S(O)2NRIRII wherein each RI and RII = H or C1-6 alkyl; n = 0-3; R4 = H or C1-6 alkyl; R6 = C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -XR6. X = -CO-, -S(O)- or -S(O)2-; and R6 = C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-(C1-6hydroxyalkyl)-, heteroaryl-(C1-6 hydroxyalkyl)-, carbocyclyl-(C1-6 hydroxyalkyl)-, heterocyclyl-(C1-6 hydroxyalkyl)-, aryl-(C1-6alkyl)-O-, heteroaryl-(C1-6alkyl)-O-, carbocyclyl-(C1-6 alkyl)-O-, heterocyclyl-(C1-6 alkyl)-O- or -NRIRII wherein each RI and RII = H, C1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)- or heterocyclyl-(C1-6 alkyl)-. Although the methods of preparation are not claimed, .apprx.80 example prepns. are included. For example, II was prepared by N-acetylation of 3-amino-5-phenyl-1,3- dihydrobenzo[e][1,4]diazepin-2-one; the reactant was prepared by deprotection of (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3- yl)carbamic acid benzyl ester, which was prepared by cyclization of (2-aminophenyl)phenylmethanone with (benzotriazol-1-yl)(benzyloxycarbonylamino)acetic acid, which was prepared from glyoxylic acid monohydrate, benzotriazole and benzyl carbamate in toluene. Values for inhibition of RSV and toxicity were determined for >100 examples of I.

IT 108895-98-3P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aminobenzodiazepinones and pharmaceutical compns. containing them for use against respiratory syncytial virus)

RN 108895-98-3 HCAPLUS

CN Carbamic acid, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (CA INDEX NAME)



IT 103373-21-3P, 3,4-Dichloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 116842-74-1P, Pyrazine-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 119506-69-3P, 1-(3-Methoxyphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 150964-48-0P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 168162-29-6P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl ester 296115-23-3P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(m-tolyl)urea 368870-46-6P, Thiophene-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 368870-49-9P, Thiophene-2-carboxylic acid N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 368870-50-2P, Furan-2-carboxylic acid N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-02-2P, 3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-04-4P, 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-09-9P, 3-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-15-7P, 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-16-8P, (S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-27-1P, 2-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-28-2P, 3-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-29-3P, 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-30-6P, 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-36-2P, 5-Phenyl-3-(2-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-37-3P, 5-Phenyl-3-(3-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-38-4P, 5-Phenyl-3-(4-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-44-2P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-methoxybenzamide 676128-51-1P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(2-trifluoromethylphenyl)acetamide 676128-52-2P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(3-trifluoromethylphenyl)acetamide 676128-53-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(4-trifluoromethylphenyl)acetamide 676128-57-7P, 1-(2-Chlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-59-9P, 1-(4-Chlorophenyl)-3-(2-oxo-5-phenyl-2,3-

dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-61-3P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(p-tolyl)urea 676128-62-4P, 1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-63-5P, (S)-1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-64-6P, 1-(4-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-66-8P, (S)-4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-67-9P, 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-68-0P, (S)-5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-69-1P, 6-Fluoro-4H-benzo[1,3]dioxin-8-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-70-4P, (S)-6-Fluoro-4H-benzo[1,3]dioxin-8-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-71-5P, (S)-2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-trifluoromethylbenzamide 676128-72-6P, 2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-73-7P, (S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-74-8P, 2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-75-9P, (S)-2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-76-0P, 1H-Indole-7-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-77-1P, (S)-1H-Indole-7-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-78-2P, 3-Methoxynaphthalene-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-79-3P, (S)-3-Methoxynaphthalene-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-80-6P, N-[7-Chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-methoxybenzamide 676128-81-7P, 1-(2-Fluorobenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-82-8P, 1-(4-Methoxybenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-83-9P, 1-(3-Methylbenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-84-0P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethylphenyl)urea 676128-85-1P, 4-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-86-2P, 4-Methoxy-3-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-87-3P, 3-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-88-4P, 5-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-89-5P, 5-Fluoro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-90-8P, 5-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-91-9P, 3-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-92-0P, 3-(2-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-93-1P, 3-(3-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-94-2P,

3-(4-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-95-3P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-methoxybenzamide 676128-96-4P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-methoxybenzamide 676128-97-5P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-nitrobenzamide 676128-98-6P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitrobenzamide 676128-99-7P, 4-Methoxy-N-[2-oxo-5-(4-trifluoromethylphenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-00-3P, 2-Methoxy-N-[2-oxo-5-(3-trifluoromethylphenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-01-4P, 4-Methoxy-N-[2-oxo-5-(3-trifluoromethylphenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-02-5P, 2-Ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-03-6P, 2,4-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-04-7P, 2-Bromo-5-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-05-8P, 2-Methoxy-N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-06-9P, N-[5-(3-Methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitrobenzamide 676129-07-0P, 2-Methoxy-N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-08-1P, 2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-09-2P, 2-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-10-5P, 1-(3,5-Dimethylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-11-6P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethoxyphenyl)urea 676129-12-7P, 1-(4-Bromo-2-trifluoromethylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-13-8P, 1-(4-Bromobenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-14-9P, 1-(2,3-Dichlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-15-0P, 1-(2,6-Dimethylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-16-1P, 1-(2-Chloro-6-methylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-17-2P, 1-(4-Nitrophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-18-3P, 1-(2-Methylsulfanylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-19-4P , 1-(2,6-Dichlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-20-7P, 5-tert-Butyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-21-8P, 2,5-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-22-9P, 1-(2,6-Difluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-23-0P, 1-(3-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-25-2P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(3-trifluoromethylphenyl)urea 676129-27-4P, 1-(3-Chlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)urea 676129-29-6P, 2-Methoxy-4-methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-30-9P, 4-(Methanesulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-31-0P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamic acid methyl ester 676129-32-1P, 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-33-2P, 2,6-Difluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-34-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-propoxybenzamide 676129-35-4P, 2-Iodo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-36-5P, 3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamic acid methyl ester 676129-37-6P, 4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-38-7P, 2-Methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-39-8P, 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-sulfamoylbenzamide 676129-40-1P, 2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenylpropionamide 676129-41-2P, 3-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenylpropionamide 676129-42-3P, 3-(2-Fluorophenyl)-1-methyl-1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-43-4P, 2-Methoxy-N-methyl-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-44-5P, 1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-45-6P, 1-Cyclohexyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-46-7P, 1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-47-8P, 1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-48-9P, 4,5-Dimethylfuran-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-49-0P, Piperidine-1-carboxylic acid N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-50-3P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide 676129-51-4P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isobutyramide 676129-52-5P, Furan-2-carboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-53-6P, Thiophene-2-carboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-54-7P, Cyclohexanecarboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-55-8P, Piperidine-1-carboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-56-9P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isonicotinamide 676129-57-0P, 5-Methylfuran-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-58-1P, N-[5-(3-Methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isobutyramide 676129-59-2P, Thiophene-2-carboxylic acid N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-60-5P, Cyclohexanecarboxylic acid

N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-61-6P, Piperidine-1-carboxylic acid
N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-62-7P, Piperidine-4-carboxylic acid
N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-63-8P, Cyclohexanecarboxylic acid
N-(8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-64-9P, Thiophene-2-carboxylic acid
N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-65-0P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(thiophen-2-yl)urea 676129-66-1P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(thiophen-3-yl)urea 676129-67-2P, Pyridine-2-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-68-3P, 1H-Pyrazole-4-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-69-4P, 6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide 676129-70-7P, 2-Ethoxynaphthalene-1-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-71-8P, 9-Oxo-9H-fluorene-1-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-72-9P, 2-Oxo-2,3-dihydrobenzimidazole-1-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-73-0P, (S)-4,5-Dibromofuran-2-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-74-1P, (S)-Benzofuran-2-carboxylic acid
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-75-2P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid methyl ester 676129-76-3P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid ethyl ester 676129-77-4P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid isobutyl ester 676129-78-5P, 2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(thiophen-2-yl)acetamide
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminobenzodiazepinones and pharmaceutical compns. containing them for use against respiratory syncytial virus)

RN 103373-21-3 HCAPLUS
CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 116842-74-1 HCAPLUS
CN 2-Pyrazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 119506-69-3 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methoxyphenyl)- (CA INDEX NAME)



RN 150964-48-0 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 168162-29-6 HCAPLUS
CN Carbamic acid, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 206115-23-3 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)- (CA INDEX NAME)



RN 368870-46-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 368870-49-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 368870-50-2 HCAPLUS
CN 2-Furancarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-02-2 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (CA INDEX NAME)



RN 676128-04-4 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)



RN 676128-09-9 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-nitro- (CA INDEX NAME)



RN 676128-15-7 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-nitro- (CA INDEX NAME)



RN 676128-16-8 HCAPLUS
CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-nitro- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-27-1 HCAPLUS
CN Benzenesulfonamide, 2-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-28-2 HCAPLUS
CN Benzenesulfonamide, 3-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-29-3 HCAPLUS
CN Benzenesulfonamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-30-6 HCAPLUS
CN Benzenesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-fluoro- (CA INDEX NAME)



RN 676128-36-2 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[2-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)



RN 676128-37-3 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)



RN 676128-38-4 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)



RN 676128-44-2 HCAPLUS
CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (CA INDEX NAME)



RN 676128-51-1 HCAPLUS
CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(trifluoromethyl)- (CA INDEX NAME)



RN 676128-52-2 HCAPLUS
CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 676128-53-3 HCAPLUS
CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 676128-57-7 HCAPLUS
CN Urea, N-(2-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-59-9 HCAPLUS
CN Urea, N-(4-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-61-3 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-methylphenyl)- (CA INDEX NAME)



RN 676128-62-4 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)- (CA INDEX NAME)



RN 676128-63-5 HCAPLUS
CN Urea, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(2-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-64-6 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-fluorophenyl)- (CA INDEX NAME)



RN 676128-66-8 HCAPLUS
CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-67-9 HCAPLUS
CN Benzamide, 5-acetyl-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (CA INDEX NAME)



RN 676128-68-0 HCAPLUS
CN Benzamide, 5-acetyl-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-ethoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-69-1 HCAPLUS
CN 4H-1,3-Benzodioxin-8-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-fluoro- (CA INDEX NAME)



RN 676128-70-4 HCAPLUS
CN 4H-1,3-Benzodioxin-8-carboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-6-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-71-5 HCAPLUS
CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-72-6 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,4,5-trifluoro- (CA INDEX NAME)



RN 676128-73-7 HCAPLUS
CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2,4,5-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-74-8 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-hydroxy- (CA INDEX NAME)



RN 676128-75-9 HCAPLUS
CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-76-0 HCAPLUS
CN 1H-Indole-7-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-77-1 HCAPLUS
CN 1H-Indole-7-carboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-78-2 HCAPLUS
CN 2-Naphthalenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (CA INDEX NAME)



RN 676128-79-3 HCAPLUS
CN 2-Naphthalenecarboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-80-6 HCAPLUS
CN Benzamide, N-[7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (CA INDEX NAME)



RN 676128-81-7 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(2-fluorophenyl)methyl]- (CA INDEX NAME)



RN 676128-82-8 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 676128-83-9 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(3-methylphenyl)methyl]- (CA INDEX NAME)



RN 676128-84-0 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 676128-85-1 HCAPLUS
CN Benzamide, 4-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)



RN 676128-86-2 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy-3-nitro- (CA INDEX NAME)



RN 676128-87-3 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy-2-nitro- (CA INDEX NAME)



RN 676128-88-4 HCAPLUS
CN Benzamide, 5-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)



RN 676128-89-5 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-fluoro-2-methoxy- (CA INDEX NAME)



RN 676128-90-8 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methoxy-2-nitro- (CA INDEX NAME)



RN 676128-91-9 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy-4-nitro- (CA INDEX NAME)



RN 676128-92-0 HCAPLUS
CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)



RN 676128-93-1 HCAPLUS
CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (CA INDEX NAME)



RN 676128-94-2 HCAPLUS
CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (CA INDEX NAME)



RN 676128-95-3 HCAPLUS
CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (CA INDEX NAME)



RN 676128-96-4 HCAPLUS
CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (CA INDEX NAME)



RN 676128-97-5 HCAPLUS
CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-nitro- (CA INDEX NAME)



RN 676128-98-6 HCAPLUS
CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-nitro- (CA INDEX NAME)



RN 676128-99-7 HCAPLUS
CN Benzamide, N-[2,3-dihydro-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (CA INDEX NAME)



RN 676129-00-3 HCAPLUS
CN Benzamide, N-[2,3-dihydro-2-oxo-5-[3-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (CA INDEX NAME)



RN 676129-01-4 HCAPLUS
CN Benzamide, N-[2,3-dihydro-2-oxo-5-[3-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (CA INDEX NAME)



RN 676129-02-5 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (CA INDEX NAME)



RN 676129-03-6 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,4-dimethoxy- (CA INDEX NAME)



RN 676129-04-7 HCAPLUS
CN Benzamide, 2-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methoxy- (CA INDEX NAME)



RN 676129-05-8 HCAPLUS
CN Benzamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (CA INDEX NAME)



RN 676129-06-9 HCAPLUS
CN Benzamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-nitro- (CA INDEX NAME)



RN 676129-07-0 HCAPLUS
CN Benzamide, N-(2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)



RN 676129-08-1 HCAPLUS
CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(methylsulfonyl)- (CA INDEX NAME)



RN 676129-09-2 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(dimethylamino)- (CA INDEX NAME)



RN 676129-10-5 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3,5-dimethylphenyl)- (CA INDEX NAME)



RN 676129-11-6 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 676129-12-7 HCAPLUS
CN Urea, N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-13-8 HCAPLUS
CN Urea, N-[(4-bromophenyl)methyl]-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-14-9 HCAPLUS
CN Urea, N-(2,3-dichlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-15-0 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2,6-dimethylphenyl)- (CA INDEX NAME)



RN 676129-16-1 HCAPLUS
CN Urea, N-(2-chloro-6-methylphenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-17-2 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-nitrophenyl)- (CA INDEX NAME)



RN 676129-18-3 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[2-(methylthio)phenyl]- (CA INDEX NAME)



RN 676129-19-4 HCAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-20-7 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(1,1-dimethylethyl)-2-methoxy- (CA INDEX NAME)



RN 676129-21-8 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,5-dimethoxy- (CA INDEX NAME)



RN 676129-22-9 HCAPLUS
CN Urea, N-(2,6-difluorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-23-0 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-fluorophenyl)- (CA INDEX NAME)



RN 676129-25-2 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 676129-27-4 HCAPLUS
CN Urea, N-(3-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-29-6 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(methylthio)- (CA INDEX NAME)



RN 676129-30-9 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(methylsulfonyl)- (CA INDEX NAME)



RN 676129-31-0 HCAPLUS
CN Benzoic acid, 4-[[(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]-, methyl ester (CA INDEX NAME)



RN 676129-32-1 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-fluoro- (CA INDEX NAME)



RN 676129-33-2 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,6-difluoro- (CA INDEX NAME)



RN 676129-34-3 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-propoxy- (CA INDEX NAME)



RN 676129-35-4 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-iodo- (CA INDEX NAME)



RN 676129-36-5 HCAPLUS
CN Benzoic acid, 4-[[(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]-3-methoxy-, methyl ester (CA INDEX NAME)



RN 676129-37-6 HCAPLUS
CN Benzamide, 4-amino-5-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)



RN 676129-38-7 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(methylthio)- (CA INDEX NAME)



RN 676129-39-8 HCAPLUS
CN Benzamide, 5-(aminosulfonyl)-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)



RN 676129-40-1 HCAPLUS
CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-α-hydroxy- (CA INDEX NAME)



RN 676129-41-2 HCAPLUS
CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-β-hydroxy- (CA INDEX NAME)



RN 676129-42-3 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)-N-methyl- (CA INDEX NAME)



RN 676129-43-4 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-N-methyl-4-nitro- (CA INDEX NAME)



RN 676129-44-5 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 676129-45-6 HCAPLUS
CN Urea, N-cyclohexyl-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-46-7 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-ethyl- (CA INDEX NAME)



RN 676129-47-8 HCAPLUS
CN Urea, N-butyl-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-48-9 HCAPLUS
CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4,5-dimethyl- (CA INDEX NAME)



RN 676129-49-0 HCAPLUS
CN 1-Piperidinecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-50-3 HCAPLUS
CN Acetamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 676129-51-4 HCAPLUS
CN Propanamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methyl- (CA INDEX NAME)



RN 676129-52-5 HCAPLUS
CN 2-Furancarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 676129-53-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 676129-54-7 HCAPLUS
CN Cyclohexanecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 676129-55-8 HCAPLUS
CN 1-Piperidinecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 676129-56-9 HCAPLUS
CN 4-Pyridinecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 676129-57-0 HCAPLUS
CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methyl- (CA INDEX NAME)



RN 676129-58-1 HCAPLUS
CN Propanamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methyl- (CA INDEX NAME)



RN 676129-59-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 676129-60-5 HCAPLUS
CN Cyclohexanecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-

benzodiazepin-3-yl]- (CA INDEX NAME)



RN 676129-61-6 HCAPLUS
CN 1-Piperidinecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 676129-62-7 HCAPLUS
CN 4-Piperidinecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 676129-63-8 HCAPLUS
CN Cyclohexanecarboxamide, N-(8-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-64-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-65-0 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-2-thienyl- (CA INDEX NAME)



RN 676129-66-1 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-3-thienyl- (CA INDEX NAME)



RN 676129-67-2 HCAPLUS
CN 2-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-68-3 HCAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676129-69-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(dimethylamino)- (CA INDEX NAME)



RN 676129-70-7 HCAPLUS
CN 1-Naphthalenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (CA INDEX NAME)



RN 676129-71-8 HCAPLUS
CN 9H-Fluorene-1-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-9-oxo- (CA INDEX NAME)



RN 676129-72-9 HCAPLUS
CN 1H-Benzimidazole-1-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-dihydro-2-oxo- (CA INDEX NAME)



RN 676129-73-0 HCAPLUS
CN 2-Furancarboxamide, 4,5-dibromo-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 676129-74-1 HCAPLUS
CN 2-Benzofurancarboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 676129-75-2 HCAPLUS
CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 676129-76-3 HCAPLUS
CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 676129-77-4 HCAPLUS
CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 676129-78-5 HCAPLUS
CN 2-Thiopheneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-α-oxo- (CA INDEX NAME)



IT 4173-63-1P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 70890-53-9P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 103373-17-7P, 2-Chloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 368879-47-7P, Furan-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676127-95-0P,

1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676127-96-1P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676127-97-2P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)butyramide 676127-98-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)isobutyramide 676127-99-4P, 2,2-Dimethyl-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-00-0P, Cyclopentanecarboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-01-1P, Cyclohexanecarboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-03-3P, 4-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-05-5P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-trifluoromethylbenzamide 676128-06-6P, Piperidine-1-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-07-7P, Morpholine-4-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-08-8P, 4-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-10-2P, 4-Methylpiperazine-1-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-11-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-trifluoromethylbenzamide 676128-12-4P, 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-13-5P, 2-Methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-14-6P, 2-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-17-9P, Benzo[b]thiophene-3-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-18-0P, 2,3-Dihydrobenzofuran-5-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-19-1P, Isoxazole-5-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-20-4P, Benzo[b]thiophene-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-21-5P, Thiophen-3-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-22-6P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)isonicotinamide 676128-23-7P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide 676128-24-8P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)methanesulfonamide 676128-25-9P, Propane-1-sulfonic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-26-0P, Butane-1-sulfonic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-31-7P, 3-(2-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-32-8P, 3-(3-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-33-9P, 3-(4-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-34-0P, 3-(2-Methoxybenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-35-1P, 3-(3-Methoxybenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-39-5P, 3-[(Furan-2-ylmethyl)amino]-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-40-8P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)isobutyramide 676128-41-9P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)methanesulfonamide 676128-42-0P, Cyclohexanecarboxylic acid

N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-43-1P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-methoxybenzamide 676128-45-3P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-nitrobenzamide 676128-46-4P, 2-(2-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 676128-47-5P, 2-(3-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 676128-48-6P, 2-(4-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 676128-49-7P, 2-(4-Nitrophenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 676128-50-0P, 2-(3-Nitrophenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 676128-54-4P, 1-(2-Methoxyphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-55-5P, 1-(2-Nitrophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-65-7P, 4-(Methanesulfonyl)-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-79-6P, 6-(Morpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminobenzodiazepinones and pharmaceutical compns. containing them for use against respiratory syncytial virus)

RN 4173-63-1 HCAPLUS
CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 70890-53-8 HCAPLUS
CN Acetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 103373-17-7 HCAPLUS
CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 368870-47-7 HCAPLUS
CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676127-95-0 HCAPLUS
CN Urea, N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N,N-diethyl- (CA INDEX NAME)



RN 676127-96-1 HCAPLUS
CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676127-97-2 HCAPLUS
CN Butanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676127-98-3 HCAPLUS
CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (CA INDEX NAME)



RN 676127-99-4 HCAPLUS
CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,2-dimethyl- (CA INDEX NAME)



RN 676128-00-0 HCAPLUS
CN Cyclopentanecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-01-1 HCAPLUS
CN Cyclohexanecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-03-3 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (CA INDEX NAME)



RN 676128-05-5 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 676128-06-6 HCAPLUS
CN 1-Piperidinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-07-7 HCAPLUS
CN 4-Morpholinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-08-8 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-nitro- (CA INDEX NAME)



RN 676128-10-2 HCAPLUS
CN 1-Piperazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methyl- (CA INDEX NAME)



RN 676128-11-3 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(trifluoromethyl)- (CA INDEX NAME)



RN 676128-12-4 HCAPLUS
CN Benzamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-13-5 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (CA INDEX NAME)



RN 676128-14-6 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-nitro- (CA INDEX NAME)



RN 676128-17-9 HCAPLUS
CN Benzo[b]thiophene-3-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-18-0 HCAPLUS
CN 5-Benzofurancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-dihydro- (CA INDEX NAME)



RN 676128-19-1 HCAPLUS
CN 5-Isoxazolecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-20-4 HCAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-21-5 HCAPLUS
CN 3-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-22-6 HCAPLUS
CN 4-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-23-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-24-8 HCAPLUS
CN Methanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-25-9 HCAPLUS
CN 1-Propanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-26-0 HCAPLUS
CN 1-Butanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-31-7 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[(2-nitrophenyl)methyl]amino]-5-phenyl- (CA INDEX NAME)



RN 676128-32-8 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[(3-nitrophenyl)methyl]amino]-5-phenyl- (CA INDEX NAME)



RN 676128-33-9 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[(4-nitrophenyl)methyl]amino]-5-phenyl- (CA INDEX NAME)



RN 676128-34-0 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[(2-methoxyphenyl)methyl]amino]-5-phenyl- (CA INDEX NAME)



RN 676128-35-1 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[(3-methoxyphenyl)methyl]amino]-5-phenyl- (CA INDEX NAME)



RN 676128-39-5 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-[(2-furanylmethyl)amino]-1,3-dihydro-5-phenyl- (CA INDEX NAME)



RN 676128-40-8 HCAPLUS
CN Propanamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (CA INDEX NAME)



RN 676128-41-9 HCAPLUS
CN Methanesulfonamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-42-0 HCAPLUS
CN Cyclohexanecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-43-1 HCAPLUS
CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)



RN 676128-45-3 HCAPLUS
CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-nitro- (CA INDEX NAME)



RN 676128-46-4 HCAPLUS
CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (CA INDEX NAME)



RN 676128-47-5 HCAPLUS
CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (CA INDEX NAME)



RN 676128-48-6 HCAPLUS
CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (CA INDEX NAME)



RN 676128-49-7 HCAPLUS
CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-nitro- (CA INDEX NAME)



RN 676128-50-0 HCAPLUS
CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-nitro- (CA INDEX NAME)



RN 676128-54-4 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-methoxyphenyl)- (CA INDEX NAME)



RN 676128-55-5 HCAPLUS
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-nitrophenyl)- (CA INDEX NAME)



RN 676128-65-7 HCAPLUS
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(methylsulfonyl)- (CA INDEX NAME)



RN 676129-79-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(4-morpholinyl)- (CA INDEX NAME)



IT 103343-47-1P, 3-Amino-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 103343-61-9P, [(1S)-1-[((3S)-2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl]-2-phenylethyl]carbamic acid tert-butyl ester 116842-76-3P, (2S)-2-Amino-N-((3S)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenylpropanamide 155452-87-2P, (7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester 253135-95-4P, (S)-3-Amino-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676127-92-7P, 3-Amino-7-chloro-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one hydrobromide 676127-93-8P, (2S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-2-(3-phenylthioureido)propanamide 676127-94-9P, (S)-3-Amino-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one acetate RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminobenzodiazepinones and pharmaceutical compns. containing
them for use against respiratory syncytial virus)
RN 103343-47-1 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-5-phenyl- (CA INDEX NAME)



RN 103343-61-9 HCAPLUS
CN Carbamic acid, [(1S)-2-[[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 116842-76-3 HCAPLUS
CN Benzenepropanamide, α-amino-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 155452-87-2 HCAPLUS
CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 253135-95-4 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-5-phenyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 676127-92-7 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-7-chloro-1,3-dihydro-5-phenyl-, hydrobromide (1:1) (CA INDEX NAME)



RN 676127-93-8 HCAPLUS
CN Benzenepropanamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-α-[[(phenylamino)thioxomethyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 676127-94-9 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1,3-dihydro-5-phenyl-, (3S)-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 253135-95-4
CMF C15 H13 N3 O

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 15 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:652131 HCAPLUS Full-text
DOCUMENT NUMBER: 139:214237
TITLE: Preparation of nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
INVENTOR(S): Scaramuzzino, Giovanni
PATENT ASSIGNEE(S): Italy
SOURCE: Eur. Pat. Appl., 313 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1336602	A1	20030820	EP 2002-425075	20020213 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LI, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			EP 2002-425075	20020213 <--

GI



II

AB New pharmaceutical compds. of general formula F-(X)q (I) [q = 1-5, preferably 1; F is chosen among drugs such as δ-tocopherol, clidanac, diethylhomospermine, glucosamine, thymocartin, vofopitant, etc.; X is chosen among 4 groups M, T, V, and Y where M = ONO2, nitrate salt, nitrite ester, ONO, thoinitrite, SNO, etc., T = OR1-M, OR1OR1-M, SR1NR2R1-M, NR2R1-M, NR2R1SR1-M, etc., R1 = saturated or unsatd., linear or branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd., optionally heterosubstituted or branched cycloalkylene, having 3 to 7 carbon atoms or an optionally heterosubstituted arylene having 3 to 7 carbon atoms; R2 = H, saturated or unsatd., linear or branched 1-21 carbon atom alkyl, saturated or unsatd. optionally heterosubstituted or branched 3-7 carbon cycloalkyl, optionally heterosubstituted 3-7 carbon aryl; R1, R2 = OH, SH, F, Cl, Br, OPO3H2, CO2H, etc.; bond between F and T = carboxylic ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.; V = Z-M2, OZ-M2, NR2Z-M2, R1Z-M2, OR1-M2, OR1Z-M2, M2 = M, R1-M, OR1-M, SR1-M, NR2R1-M; ZM2 =

COCH2CH(M2)CH2N+Me3, COCH2CH2COM2, COCH(NHR2)CH2M2, etc.; Y = 4-COC6H4CH2ONO2, O(CH2)4ONO2, COCH(NH2)CH2ONO2, 3-OC6H4CH2ONO2, etc.] were prepared For example, α-tocopherol reacted with 4-HO2CC6H4CH2ONO2 to give the nitroxymethyl derivative II. The compds. of general formula I are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

IT 586348-84-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrate prodrugs for treating or preventing inflammatory, ischemic, degenerative, and proliferative diseases)

RN 586348-84-7 HCAPLUS

CN 4-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 179024-48-7
CMF C24 H20 N4 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 7697-37-2
CMF H N O3

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:849588 HCAPLUS Full-text
DOCUMENT NUMBER: 137:353054
TITLE: Preparation of pyrimidinylaminothiazolecarboxylates and related pyrimidines as dual inhibitors of phosphodiesterases PDE 7 and PDE 4

INVENTOR(S): Pitts, William John; Watson, Andrew J.; Dodd, John H.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088080	A2	20021107	WO 2002-US13742	20020430 <--
WO 2002088080	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2444436	A1	20021107	CA 2002-2444436	20020430 <--
AU 2002256419	A1	20021111	AU 2002-256419	20020430 <--
US 20030104974	A1	20030605	US 2002-135998	20020430 <--
EP 1383743	A2	20040128	EP 2002-725882	20020430 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2004000718	A2	20040728	HU 2004-718	20020430 <--
JP 2004532233	T	20041021	JP 2002-585382	20020430 <--
US 20060116516	A1	20060601	US 2005-281246	20051117 <--

PRIORITY APPLN. INFO.:	US 2001-287964P	P	20010501 <--
	US 2001-299287P	P	20010619 <--
	US 2002-368752P	P	20020329 <--
	WO 2002-US13742	W	20020430 <--
	US 2002-173322	A3	20020617 <--

OTHER SOURCE(S): MARPAT 137:353054
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Dual inhibitors of PDE 7 and PDE 4 (pyrimidines, e.g. I), together with their use to treat leukocyte activation-associated disorders (including transplant rejection, rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, chronic obstructive pulmonary disease, lupus and multiple sclerosis), are provided herein. The present invention further provides for a method of reducing or alleviating nausea and emesis associated with the administration of PDE4 inhibitors comprising either the administration of a dual PDE 7-PDE 4 inhibitor, or the simultaneous or sequential co-administration of a selective PDE 7 inhibitor together with a selective PDE 4 inhibitor. In I, R1a is H or alkyl; R2a is optionally substituted heteroaryl; Z is halogen, alkyl, substituted alkyl, haloalkyl, or NR3aR4a; R3a is H or alkyl; R4a is alkyl, optionally substituted (heteroaryl)alkyl, optionally substituted heterocyclo, optionally substituted (heterocyclo)alkyl, or (aryl)alkyl wherein the aryl group is substituted with one or two groups T1* and T2* and optionally further substituted with a group T3*; or R3a and R4a together with the N atom to which they are attached may combine to form an optionally substituted heterocyclo

ring; R5a is (aryl)alkyl wherein the aryl group is substituted with one or two groups T1* and T2* and optionally further substituted with a group T3*; R6a is H or alkyl; R7a is H or alkyl; T1* and T2* are independently alkoxy, alkoxycarbonyl, heteroaryl or -SO2R8a where R8a is alkyl, amino, alkylamino or dialkylamino; or T1* and T2* together with the atoms to which they are attached may combine to form a ring (e.g., benzodioxole); T3* is H, alkyl, halo, haloalkyl or cyano. Other pyrimidine classes (II-V) are described in the claims; this patent differs from WO 02/088079 with regard to IV (J1 and J2 are same or different and are optionally substituted alkylene group of 1-3 C atoms, provided that they are not both greater than C2 alkylene). Pharmaceutical properties for 2-[[4-[4-(dimethylamino)-1-piperidinyl]-6-[[(3,4,5-trimethoxyphenyl)methyl]amino]-2-pyrimidinyl]amino]-4-methyl-5-thiazolecarboxylic acid Et ester (F1) and 2-[4,6-bis(4-hydroxypiperidin-1-yl)pyrimidin-2-ylamino]-4-methylthiazole-5- carboxylic acid Et ester (F2) are reported. F1 is 100 fold selective for PDE 7 over PDE 4 and F2 is >50 fold selective for PDE 7. The IC50 for lipolysaccharide peripheral blood mononuclear cells tumor necrosis factors (LPS PBMC TNF) was >25 μM for F2 while cilomilast was potent in this assay with an IC50 of 0.43 μM. Mice were administered 30 mg/kg IP of F1 and 45 min later were administered 10 mg of rolipram orally; the Cmax for F1 are essentially unchanged by co-administration of rolipram, and the Cmax of rolipram was reduced by a factor of 3 by co-administration with F1. Also, the plasma concentration of F1 when administered at 30 mg/kg does not reach the PDE 4 IC50 of F1. Compared to LPS-injected mice pretreated with vehicle, mice receiving F1 or rolipram alone had 52% and 54% redns. in serum TNF, resp. (each p<.05 vs. vehicle), as measured by a specific immunoassay, whereas mice treated with the combination of rolipram plus F1 showed an 89% reduction in serum TNF, which was significantly (p<.05) less than mice receiving either compound alone. Mice treated with dexamethasone showed a 93% reduction in serum TNF. Compound F2 inhibited TNF production by 33.7% which was not statistically significant, whereas cilomilast inhibited TNF production by 56% (p < 0.05); the combination group which received both cilomilast 1 mg/kg and compound F2, had a decrease in TNF production of 72% (p < 0.05 vs. cilomilast alone). Although the methods of preparation are not claimed, 27 example prepns. are included.

IT 197894-84-1, PD 189659
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PDE 4 inhibitor; combined with pyrimidine PDE 7 inhibitors for reducing emesis or nausea associated with administration of PDE 4 inhibitor for treatment of leukocyte activation-associated diseases)

RN 197894-84-1 HCAPLUS

CN 3-Pyridinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 17 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:849587 HCAPLUS Full-text
DOCUMENT NUMBER: 137:353053

TITLE: Preparation of pyrimidinylaminothiazolecarboxylates and related pyrimidines as dual inhibitors of phosphodiesterases PDE 7 and PDE 4

INVENTOR(S): Pitts, William John; Watson, Andrew J.; Dodd, John H.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088079	A2	20021107	WO 2002-US13628	20020429 <--
WO 2002088079	A3	20030130		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002305290	A1	20021111	AU 2002-305290	20020429 <--
US 20030104974	A1	20030605	US 2002-135998	20020430 <--
US 20060116516	A1	20060601	US 2005-281246	20051117 <--

PRIORITY APPLN. INFO.:

US 2001-287964P	P	20010501 <--
US 2001-299287P	P	20010619 <--
US 2002-368752P	P	20020329 <--
WO 2002-US13628	W	20020429 <--
US 2002-173322	A3	20020617 <--

OTHER SOURCE(S): MARPAT 137:353053

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Dual inhibitors of PDE7 and PDE4, together with their use to treat leukocyte activation-associated disorders (including transplant rejection, rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, chronic obstructive pulmonary disease, lupus and multiple sclerosis), are provided herein. Dual inhibitors of PDE 7 and PDE 4 (pyrimidines, e.g. I), together with their use to treat leukocyte activation-associated disorders (including transplant rejection, rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, chronic obstructive pulmonary disease, lupus and multiple sclerosis), are provided herein. The present invention further provides for a method of reducing or alleviating nausea and emesis associated with the administration of PDE4 inhibitors comprising either the administration of a dual PDE 7-PDE 4 inhibitor, or the simultaneous or sequential co-administration of a selective PDE 7 inhibitor together with a selective PDE 4 inhibitor. In I, R1a is H or alkyl; R2a is optionally substituted heteroaryl; Z is halogen, alkyl, substituted alkyl, haloalkyl, or NR3aR4a; R3a is H or alkyl; R4a is alkyl, optionally substituted (heteroaryl)alkyl, optionally substituted heterocyclo, optionally substituted (heterocyclo)alkyl, or (aryl)alkyl wherein the aryl group is substituted with one or two groups T1* and T2* and optionally further substituted with a group T3*; or R3a and R4a together with the N atom to which

they are attached may combine to form an optionally substituted heterocyclo ring; R5a is (aryl)alkyl wherein the aryl group is substituted with one or two groups T1* and T2* and optionally further substituted with a group T3*; R6a is H or alkyl; R7a is H or alkyl; T1* and T2* are independently alkoxy, alkoxycarbonyl, heteroaryl or -SO2R8a where R8a is alkyl, amino, alkylamino or dialkylamino; or T1* and T2* together with the atoms to which they are attached may combine to form a ring (e.g., benzodioxole); T3* is H, alkyl, halo, haloalkyl or cyano. Other pyrimidine classes (II-V) are described in the claims; this patent differs om WO 02/088080 with regard to IV (J1 and J2 are same or different and are a bond or optionally substituted alkylene group of 1-4 C atoms, provided that they are not both a bond, and further that if one is a bond the other is an alkylene group of at least 3 C atoms). Pharmaceutical properties for 2-[[4-[4-(dimethylamino)-1-piperidinyl]-6-[[(3,4,5- trimethoxyphenyl)methyl]amino]-2-pyrimidinyl]amino]-4-methyl-5-thiazolecarboxylic acid Et ester (F1) and 2-[4,6-bis(4-hydroxypiperidin-1-yl)pyrimidin-2-ylamino]-4-methylthiazole-5- carboxylic acid Et ester (F2) are reported. F1 is 100 fold selective for PDE 7 over PDE 4 and F2 is >50 fold selective for PDE 7. The IC50 for lipolysaccharide peripheral blood mononuclear cells tumor necrosis factors (LPS PBMC TNF) was >25 μM for F2 while cilomilast was potent in this assay with an IC50 of 0.43 μM. Mice were administered 30 mg/kg IP of F1 and 45 min later were administered 10 mg of rolipram orally; the Cmax for F1 are essentially unchanged by co-administration of rolipram, and the Cmax of rolipram was reduced by a factor of 3 by co-administration with F1. Also, the plasma concentration of F1 when administered at 30 mg/kg does not reach the PDE 4 IC50 of F1. Compared to LPS-injected mice pretreated with vehicle, mice receiving F1 or rolipram alone had 52% and 54% redns. in serum TNF, resp. (each p<.05 vs. vehicle), as measured by a specific immunoassay, whereas mice treated with the combination of rolipram plus F1 showed an 89% reduction in serum TNF, which was significantly (p<.05) less than mice receiving either compound alone. Mice treated with dexamethasone showed a 93% reduction in serum TNF. Compound F2 inhibited TNF production by 33.7% which was not statistically significant, whereas cilomilast inhibited TNF production by 56% (p < 0.05); the combination group which received both cilomilast 1 mg/kg and compound F2, had a decrease in TNF production of 72% (p < 0.05 vs. cilomilast alone). Although the methods of preparation are not claimed, 27 example prepns. are included.

IT 197894-84-1, PD 189659
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PDE 4 inhibitor; combined with pyrimidine PDE 7 inhibitors for reducing emesis or nausea associated with administration of PDE 4 inhibitor for treatment of leukocyte activation-associated diseases)

RN 197894-84-1 HCAPLUS

CN 3-Pyridinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:755195 HCAPLUS Full-text
DOCUMENT NUMBER: 137:273169
TITLE: Method of inhibiting viral infection using HMG-CoA reductase inhibitors and isoprenylation inhibitors
INVENTOR(S): Graham, Barney Scott; Gower, Tara L.; Pastey, Manoj K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020142940	A1	20021003	US 2001-981682	20011016 <--
PRIORITY APPLN. INFO.:			US 2000-241247P P	20001017 <--

AB Applicants provide methods of inhibiting viral infections, and treating an infected individual with AIDS, respiratory syncytial virus infection, parainfluenza virus infection, and other viral infections. Inhibitors of Rho isoprenylation are used to inhibit Rho cell surface attachment, thereby inhibiting the use, by viruses, of Rho as a receptor for infection of susceptible cells. Isoprenylation inhibitors include inhibitors specific for the enzymes farnesyltransferase and geranylgeranyltranferase, as well as inhibitors of general cholesterol biosynthesis, such as HMG-CoA reductase inhibitors. Mice were treated with 1 mg/day lovastatin, 50 mg/day gemfibrozil, or PBS by oral gavage beginning three days prior to infection with either RSV or vaccinia virus. Vaccinia replication and illness was not effected by lovastatin or gemfibrozil treatment compared to PBS treated controls. Gemfibrozil and PBS treated mice infected with RSV had a peak titer in the lung of 6.5+/-0.43 (log10 pfu/gm) and 6.5+/-0.19 (log10 pfu/gm), resp., while RSV replication in lovastatin treated mice was reduced by nearly 100-fold to 4.7+/-0.4 (log10 pfu/gm).

IT 149786-88-9, BZA-5B
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of inhibiting viral infection using HMG-CoA reductase inhibitors and isoprenylation inhibitors)

RN 149786-88-9 HCAPLUS
CN L-Methionine, L-cysteinyl-2,3-dihydro-3-(methylamino)-2-oxo-5-phenyl-1H-1,4-benzodiazepine-1-acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:556113 HCAPLUS Full-text

DOCUMENT NUMBER: 137:119694
TITLE: Sodium-hydrogen exchanger type 1 inhibitor combination with another agent for reduction of ischemia-associated tissue damage
INVENTOR(S): Tracey, Wayne R.; Hill, Roger J.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020099075	A1	20020725	US 2002-52320	20020117 <--
US 6423705	B2	20020723		
EP 1226830	A2	20020731	EP 2002-250403	20020121 <--
EP 1226830	A3	20030709		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1370531	A	20020925	CN 2002-102433	20020121 <--
AU 2002011978	A	20020801	AU 2002-11978	20020122 <--
JP 2002275096	A	20020925	JP 2002-12315	20020122 <--
CA 2369212	A1	20020725	CA 2002-2369212	20020123 <--
ZA 2002000597	A	20030723	ZA 2002-597	20020123 <--
HU 2002000253	A2	20021028	HU 2002-253	20020124 <--
HU 2002000253	A3	20030428		
NZ 516792	A	20030926	NZ 2002-516792	20020124 <--

PRIORITY APPLN. INFO.: US 2001-264173P P 20010125 <--
OTHER SOURCE(S): MARPAT 137:119694

AB The invention provides methods of reducing tissue damage resulting from ischemia which comprise administering to a mammal in need of such reduction an effective amount of a combination, or a pharmaceutical composition comprising such combination, of a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor and a second compound selected from the group consisting of: (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and (e) an enzyme/protein modulator. The invention further provides kits comprising an amount of a sodium-hydrogen exchanger type-1 inhibitor, and a pharmaceutically acceptable carrier, vehicle, or diluent in a first unit dosage form; an amount of a second compound selected from the group consisting of (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and (e) an enzyme/protein modulator selected from the group consisting of a protein kinase C activator, an endothelin converting enzyme inhibitor, a tissue-activated fibrinolytic inhibitor (TAFI), a Na+/Ca+2 exchanger isoform-1 (NCX-1) inhibitor, and a poly(ADP ribose) synthetase (PARS/PARP) inhibitor, and a pharmaceutically acceptable carrier, vehicle, or diluent in a second unit dosage form; and a container.

IT 443911-20-4, L 747981
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sodium-hydrogen exchanger type 1 inhibitor combination with another agent for reduction of ischemia-associated tissue damage)

RN 443911-20-4 HCAPLUS

CN Urea, N-[2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-N'-[4-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)

Currently available stereo shown.



L20 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:900053 HCAPLUS Full-text
DOCUMENT NUMBER: 136:31699
TITLE: Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease
INVENTOR(S): Doherty, Annette
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1161949	A1	20011212	EP 2000-401646	20000609 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2347337	A1	20011209	CA 2001-2347337	20010511 <--
EP 1161950	A1	20011212	EP 2001-401383	20010525 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
ZA 2001004616	A	20021030	ZA 2001-4616	20010606 <--
US 20020010175	A1	20020124	US 2001-876719	20010607 <--
US 6544983	B2	20030408		
BR 2001002289	A	20020312	BR 2001-2289	20010607 <--
NZ 512222	A	20021025	NZ 2001-512222	20010607 <--
MX 2001PA05726	A	20030820	MX 2001-PA5726	20010607 <--
NO 2001002831	A	20011210	NO 2001-2831	20010608 <--
CN 1345725	A	20020424	CN 2001-120850	20010608 <--
HU 2001002388	A2	20020429	HU 2001-2388	20010608 <--
HU 2001002388	A3	20041129		
JP 2002138090	A	20020514	JP 2001-174372	20010608 <--

PRIORITY APPLN. INFO.: EP 2000-401646 A 20000609 <--
OTHER SOURCE(S): MARPAT 136:31699
GI



I

AB The present invention relates to the use of diazepinoindoles of the formula (I): in which A is aryl or nitrogen-containing heteroaryl, and B is a hydroxyl or amino radical, for the treatment of chronic obstructive pulmonary disease.

IT 197894-73-8 197894-75-0 197894-76-1
197894-77-2 197894-81-8 197894-83-0
197894-84-1 197894-85-2 197894-91-0
197894-92-1 197894-93-2 197894-94-3
197894-95-4 197895-04-8 197895-06-0
321527-83-7
RL: PAC (Pharmacological activity); BIOL (Biological study)
(use of diazepinoindoles for treatment of chronic obstructive pulmonary disease)

RN 197894-73-8 HCAPLUS

CN 3-Isoquinolinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-hydroxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-75-0 HCAPLUS

CN Carbamic acid, [4-[[[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]amino]carbonyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-76-1 HCAPLUS

CN Benzamide, 4-amino-N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-77-2 HCAPLUS
CN Benzamide, 4-amino-N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]-3,5-dichloro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-81-8 HCAPLUS
CN Benzamide, 4-amino-N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]-5-chloro-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-83-0 HCAPLUS
CN 2-Pyridinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-84-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 197894-85-2 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-91-0 HCAPLUS
CN 2-Pyrazinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-92-1 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-93-2 HCAPLUS
CN 3-Quinolinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-94-3 HCAPLUS
CN Pyrazolo[5,1-c][1,2,4]triazine-3-carboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]-4,7-dimethyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 197894-95-4 HCAPLUS
CN Benzamide, 4-amino-3,5-dichloro-N-[(3R)-9-(dimethylamino)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 197895-04-8 HCAPLUS
CN 2-Benzofurancarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 197895-06-0 HCAPLUS
CN Pyrazolo[5,1-c][1,2,4]triazine-3-carboxamide, 4,7-dimethyl-N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenyl-9-(1-pyrrolidinyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 321527-83-7 HCAPLUS
CN Carbamic acid, [4-[[[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]amino]carbonyl]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:811123 HCAPLUS Full-text
DOCUMENT NUMBER: 134:131503
TITLE: Synthesis, Structure-Activity Relationships, and Pharmacological Profile of 9-Amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indoles: Discovery of Potent, Selective Phosphodiesterase Type 4 Inhibitors
AUTHOR(S): Burnouf, Catherine; Auclair, Eric; Avenel, Nadine; Bertin, Bernadette; Bigot, Christele; Calvet, Alain; Chan, Kam; Durand, Corinne; Fasquelle, Veronique; Feru, Frederic; Gilbertsen, Richard; Jacobelli, Henry; Kebsi, Adel; Lallier, Emmanuelle; Maignel, Jacquie; Martin, Brigitte; Milano, Stephane; Ouagued, Malika; Pascal, Yves; Pruniaux, Marie-Pierre; Puaud, Jocelyne; Rocher, Marie-Noelle; Terrasse, Christophe; Wrigglesworth, Roger; Doherty, Annette M.
CORPORATE SOURCE: Fresnes Laboratories, Pfizer Global Research & Development, Fresnes, 94265, Fr.
SOURCE: Journal of Medicinal Chemistry (2000), 43(25), 4850-4867
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:131503
GI



I

AB The synthesis, structure-activity relationships, and biol. properties of a novel series of potent and selective phosphodiesterase type 4 (PDE4) inhibitors was accomplished. These new aminodiazepinoindoles displayed in vitro PDE4 activity with submicromolar IC50 values and PDE4 selectivity vs PDE1, -3, and -5. Specifically, one compound, CI 1044 (I), provided efficient

in vitro inhibition of TNFα release from hPBMC and hWB with IC50 values of 0.34 and 0.84 μM, resp. This compound was found to exhibit potent in vivo activity in antigen-induced eosinophil recruitment in Brown-Norway rats (ED50 = 3.2 mg/kg po) and in production of TNFα in Wistar rats (ED50 = 2.8 mg/kg po). No emetic side effects at therapeutic doses were observed in ferrets.

IT 179023-93-9P 179023-97-3P 179024-04-5P
179024-08-9P 179024-09-0P 179024-11-4P
179024-12-5P 179024-27-2P 179024-28-3P
179024-29-4P 179024-47-6P 179024-48-7P, (+)-CI
1018 179024-49-8P 197894-76-1P 197894-77-2P
197894-84-1P, CI 1044 197894-85-2P 197894-86-3P
197894-92-1P 197894-93-2P 197894-94-3P
197894-95-4P 197894-96-5P 197894-99-8P
197895-05-9P 197895-06-0P 260361-27-1P
321527-78-0P 321527-80-4P 321527-81-5P
321527-82-6P 321527-83-7P 321527-84-8P
321527-85-9P 321527-86-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, SAR and pharmacol. of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indoles, potent selective phosphodiesterase type 4 inhibitors)

RN 179023-93-9 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-97-3 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-04-5 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-08-9 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-09-0 HCAPLUS
CN 3-Quinolinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-11-4 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-12-5 HCAPLUS
CN Pyrazolo[5,1-c][1,2,4]triazine-3-carboxamide, 4,7-dimethyl-N-[(3R)-3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-27-2 HCAPLUS
CN 4-Pyridinecarboxamide, 3,5-dichloro-N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-28-3 HCAPLUS
CN Carbamic acid, [4-[[[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]amino]carbonyl]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179024-29-4 HCAPLUS
CN 4-Pyridinecarboxamide, 3-amino-N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 179024-47-6 HCAPLUS
CN Benzamide, 2-methoxy-N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-48-7 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-49-8 HCAPLUS
CN Pyrazolo[5,1-c][1,2,4]triazine-3-carboxamide, 4,7-dimethyl-N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-76-1 HCAPLUS
CN Benzamide, 4-amino-N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-77-2 HCAPLUS
CN Benzamide, 4-amino-N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]-3,5-dichloro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-84-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 197894-85-2 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-86-3 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-9-(acetylamino)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 197894-92-1 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-93-2 HCAPLUS
CN 3-Quinolinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197894-94-3 HCAPLUS
CN Pyrazolo[5,1-c][1,2,4]triazine-3-carboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]-4,7-dimethyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 197894-95-4 HCAPLUS
CN Benzamide, 4-amino-3,5-dichloro-N-[(3R)-9-(dimethylamino)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 197894-96-5 HCAPLUS
CN Benzamide, 4-amino-3,5-dichloro-N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenyl-9-(1-pyrrolidinyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 197894-99-8 HCAPLUS
CN Benzamide, N-[(3R)-9-(acetylamino)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]-4-amino-3,5-dichloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 197895-05-9 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenyl-9-(1-pyrrolidinyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 197895-06-0 HCAPLUS
CN Pyrazolo[5,1-c][1,2,4]triazine-3-carboxamide, 4,7-dimethyl-N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenyl-9-(1-pyrrolidinyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 260361-27-1 HCAPLUS
CN Benzamide, 4-amino-3,5-dichloro-N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 321527-78-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-nitro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 321527-80-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 321527-81-5 HCAPLUS
CN 4-Pyridinecarboxamide, 3,5-dichloro-N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 321527-82-6 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]-3,5-dichloro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 321527-83-7 HCAPLUS
CN Carbamic acid, [4-[[[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]amino]carbonyl]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 321527-84-8 HCAPLUS
CN Benzamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 321527-85-9 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-nitro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 321527-86-0 HCAPLUS
CN 4-Pyridinecarboxamide, 3-amino-N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 126149-54-0P 126167-36-0P 126252-50-4P
179024-51-2P 179024-53-4P 179024-54-5P
179024-56-7P 179024-58-9P 179024-59-0P
197895-07-1P 197895-08-2P 197895-10-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, SAR and pharmacol. of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indoles, potent selective phosphodiesterase type 4 inhibitors)
RN 126149-54-0 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-1-phenyl- (CA INDEX NAME)



RN 126167-36-0 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-3,4-dione, 6,7-dihydro-1-phenyl-, 3-oxime (CA INDEX NAME)



RN 126252-50-4 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-1-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-51-2 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-9-methyl-1-phenyl- (CA INDEX NAME)



RN 179024-53-4 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-3,4-dione, 6,7-dihydro-9-methyl-1-phenyl-, 3-oxime (CA INDEX NAME)



RN 179024-54-5 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one,
3-amino-6,7-dihydro-9-methyl-1-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-56-7 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one,
3-amino-6,7-dihydro-9-methoxy-1-phenyl- (CA INDEX NAME)



RN 179024-58-9 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-3,4-dione,
6,7-dihydro-9-methoxy-1-phenyl-, 3-oxime (CA INDEX NAME)



RN 179024-59-0 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one,
3-amino-6,7-dihydro-9-methoxy-1-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197895-07-1 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one,
3-amino-6,7-dihydro-9-nitro-1-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197895-08-2 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one,
3,9-diamino-6,7-dihydro-1-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 197895-10-6 HCAPLUS
CN Carbamic acid, [(3R)-3,4,6,7-tetrahydro-9-nitro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 197894-75-0P 197895-13-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, SAR and pharmacol. of 9-amino-4-oxo-1-phenyl-3,4,6,7-

tetrahydro[1,4]diazepino[6,7,1-hi]indoles, potent selective phosphodiesterase type 4 inhibitors)
RN 197894-75-0 HCAPLUS
CN Carbamic acid, [4-[[[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]amino]carbonyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197895-13-9 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-1-phenyl-9-(1-pyrrolidinyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:790295 HCAPLUS Full-text
DOCUMENT NUMBER: 133:329629
TITLE: Therapeutic applications of pro-apoptotic benzodiazepines
INVENTOR(S): Glick, Gary D.; Opipari, Anthony W., Jr.
PATENT ASSIGNEE(S): The Regents of the University of Michigan, USA; Opipari, Anthony W., Jr.
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066106	A2	20001109	WO 2000-US11599	20000427 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				

```
            SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
            DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
            CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    CA 2372150          A1   20001109    CA 2000-2372150          20000427 <--
    EP 1143946          A2   20011017    EP 2000-928586           20000427 <--
    EP 1143946          A3   20020515
    EP 1143946          B1   20040128
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    JP 2002543121       T    20021217    JP 2000-614991           20000427 <--
    AT 258439           T    20040215    AT 2000-928586           20000427 <--
    EP 1398033          A2   20040317    EP 2003-27484            20000427 <--
    EP 1398033          A3   20040630
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI, CY
    PT 1143946          T    20040531    PT 2000-928586           20000427 <--
    ES 2214273          T3   20040916    ES 2000-928586           20000427 <--
    AU 782447           B2   20050728    AU 2000-46802            20000427 <--
    US 7125866          B1   20061024    US 2000-700101           20001108 <--
    US 20010016583      A1   20010823    US 2001-767283           20010122 <--
    US 7220739          B2   20070522
    MX 2001PA11052      A    20021122    MX 2001-PA11052          20011030 <--
    US 20030119029      A1   20030626    US 2002-217878           20020813 <--
    US 20050261176      A1   20051124    US 2003-427211           20030501 <--
    US 7186712          B2   20070306
    US 20040176358      A1   20040909    US 2003-634114           20030804 <--
    US 20040241781      A1   20041202    US 2004-795535           20040308 <--
    US 7276348          B2   20071002
    US 20060025388      A1   20060202    US 2004-886450           20040707 <--
    US 20050113460      A1   20050526    US 2004-935333           20040907 <--
    AU 2005227385       A1   20051201    AU 2005-227385           20051027 <--
    US 20070036854      A1   20070215    US 2006-585492           20061023 <--
    US 20070135418      A1   20070614    US 2006-643614           20061221 <--
    US 20070299059      A1   20071227    US 2007-807291           20070525 <--
    AU 2008200867       A1   20080313    AU 2008-200867           20080222
PRIORITY APPLN. INFO.:                   US 1999-131761P      P   19990430 <--
                                         US 1999-165511P      P   19991115 <--
                                         US 2000-191855P      P   20000324 <--
                                         US 1995-443540       B3  19950518 <--
                                         US 1997-881037       A2  19970623 <--
                                         US 1997-943983       B2  19971003 <--
                                         US 1998-18026        B2  19980202 <--
                                         US 1999-165855P      P   19991116 <--
                                         EP 2000-928586       A3  20000427 <--
                                         WO 2000-US11599      W   20000427 <--
                                         US 2000-700101       A1  20001108 <--
                                         US 2001-767283       A2  20010122 <--
                                         US 2001-312560P      P   20010815 <--
                                         US 2001-313689P      P   20010820 <--
                                         US 2002-396670P      P   20020718 <--
                                         US 2002-217878       A2  20020813 <--
                                         US 2003-427211       A2  20030501 <--
                                         US 2003-634114       A2  20030804 <--
                                         US 2004-795535       A2  20040308 <--
                                         AU 2004-255153       A3  20040430
                                         US 2004-886450       A2  20040707
OTHER SOURCE(S):            MARPAT 133:329629
GI
```



I

AB Benzodiazepine compds., such as 1,4-benzodiazepine-2-ones and 1,4-benzodiazepine-2,5-diones, their enantiomers, pharmaceutically acceptable salts, and prodrugs for treatment of a variety of dysregulatory disorders related to cellular death are provided. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compds. can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drugs screening assays and other diagnostic methods. For example, benzodiazepine compound I (2.5 mg/μL, i.p.) decreased the rate of tumor growth in a mouse model of human neuroblastoma. Specifically, tumors in controlled mice increased in volume 5-fold over an average 4 day period, whereas 12 days were required for the same increase in tumor size in benzodiazepine-treated animals. These findings support the claim that benzodiazepine was able to treat human malignant disease in a mouse model. Further, benzodiazepine had specific activity against human neuroblastoma both in vitro and in vivo.

IT 304681-21-8 304681-22-9 304681-23-0
304681-24-1 304681-25-2 304681-26-3
304681-27-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic applications of pro-apoptotic benzodiazepines)

RN 304681-21-8 HCAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-2,3-dihydro-5-(4-hydroxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-nitro- (CA INDEX NAME)



RN 304681-22-9 HCAPLUS
CN 4-Isoxazolecarboxamide, N-[7-chloro-2,3-dihydro-5-(4-hydroxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-5-methyl-3-phenyl- (CA INDEX NAME)



RN 304681-23-0 HCAPLUS
CN 4-Piperidinecarboxamide, 1-acetyl-N-[1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-2,3-dihydro-5-(4-hydroxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 304681-24-1 HCAPLUS
CN Pentanediamide, N1-[1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-2,3-dihydro-5-(4-hydroxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N5-phenyl- (CA INDEX NAME)



RN 304681-25-2 HCAPLUS
CN Benzamide, N-[2-[[1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-2,3-dihydro-5-(4-hydroxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]amino]-2-oxoethyl]- (CA INDEX NAME)



RN 304681-26-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-2,3-dihydro-5-(4-hydroxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (CA INDEX NAME)



RN 304681-27-4 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 3-amino-1-([1,1'-biphenyl]-4-ylmethyl)-7-chloro-1,3-dihydro-5-(4-hydroxyphenyl)- (CA INDEX NAME)



L20 ANSWER 23 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:721702 HCAPLUS Full-text
DOCUMENT NUMBER: 129:330743
ORIGINAL REFERENCE NO.: 129:67459a,67462a
TITLE: Preparation of phosphodiesterase 4-inhibiting [1,4]diazepino[6,7,1-hi]indol-4-ones
INVENTOR(S): Pascal, Yves; Burnouf, Catherine; Gaudilliere, Bernard; Jacobelli, Henry; Calvet, Alain; Payne, Adrian; Dahl, Svein Gunwald
PATENT ASSIGNEE(S): Jouveinal, Fr.
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9849169		A1	19981105	WO 1998-EP2827	19980430 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2762841		A1	19981106	FR 1997-5422	19970430 <--
FR 2762841		B1	19990702		
HR 980231		B1	20020630	HR 1998-231	19980429 <--
CA 2278217		A1	19981105	CA 1998-2278217	19980430 <--
AU 9877652		A	19981124	AU 1998-77652	19980430 <--
ZA 9803704		A	19991025	ZA 1998-3704	19980430 <--
EP 980374		A1	20000223	EP 1998-925598	19980430 <--
EP 980374		B1	20030212		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9809429		A	20000613	BR 1998-9429	19980430 <--
NZ 337589		A	20001027	NZ 1998-337589	19980430 <--
JP 2001522367		T	20011113	JP 1998-546624	19980430 <--
AT 232534		T	20030215	AT 1998-925598	19980430 <--
ES 2190083		T3	20030716	ES 1998-925598	19980430 <--
MX 9906979		A	20050419	MX 1999-6979	19990727 <--
US 6239130		B1	20010529	US 1999-380883	19991110 <--
PRIORITY APPLN. INFO.:				FR 1997-5422 A	19970430 <--
				WO 1998-EP2827 W	19980430 <--

OTHER SOURCE(S): MARPAT 129:330743

GI



I

AB The title compds. [I; A = H, C1-4 alkyl, alkoxy, OH, NO2, (un)substituted NH2, etc.; B = alkyl, CH2OM, CH2O2C(CH2)a(CO)bY1Y2, (CH2)cCO2M; Y1 = (VCH2CH2)c, NHCHR(CO); M = alkyl, H; V = NH, O; R = residue of a natural α-amino acid with the C atom to which it is linked having a (R) or (S) configuration; Y2 = H, OH, OMe, 4-morpholinyl; a = 1, 2; b = 0, 1; c = 0-2; X1, X2 = H, alkyl, halogen , CN, (un)substituted 5-tetrazolyl, etc.; Z = CH when Z1 and Z2 are CH or N, Z = N when Z1 and Z2 are CH], useful in the treatment of phosphodiesterase 4-mediated diseases [e.g., asthma, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disorders, pulmonary hypertension, liver injury, bone loss, etc. (all no data)], are prepared and I-containing formulations presented. Thus, (3R)-3-amino-1-phenyl-6,7-dihydro-3H-[1,4]diazepino[6,7,1-hi]indol-4-one was reacted with 2-acetamidobenzoic acid in the presence of O-[(ethoxycarbonyl)cyanomethylamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate, and the intermediate reacted with 1,1,1-

trimethoxyethane and cyclized, producing (3S)-3-(2-methyl-4-oxo-4H-quinazolin-3-yl)-1-phenyl-6,7-dihydro-3H- [1,4]diazepino[6,7,1-hi]indol-4-one which demonstrated a phosphodiesterase 4-inhibiting activity of 0.448 (using an enzyme preparation from the U937 cell line), vs. 0.792 for rolipram.

IT 126149-54-0 179024-51-2 179024-54-5
197895-07-1 197895-08-2 215058-13-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phosphodiesterase 4-inhibiting [1,4]diazepino[6,7,1-hi]indol-4-ones)

RN 126149-54-0 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-1-phenyl- (CA INDEX NAME)



RN 179024-51-2 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-9-methyl-1-phenyl- (CA INDEX NAME)



RN 179024-54-5 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-9-methyl-1-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197895-07-1 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-9-nitro-1-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 197895-08-2 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one,
3,9-diamino-6,7-dihydro-1-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 215098-13-8 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one,
3-amino-6,7-dihydro-9-nitro-1-phenyl- (CA INDEX NAME)



IT 215105-58-1P 215105-60-5P 215105-61-6P
215105-62-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phosphodiesterase 4-inhibiting [1,4]diazepino[6,7,1-hi]indol-4-ones)
RN 215105-58-1 HCAPLUS
CN 4-Pyridinecarboxamide, 3-amino-N-[(3S)-3,4,6,7-tetrahydro-9-nitro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 215105-60-5 HCAPLUS
CN Carbamic acid, [4-[[[(3S)-3,4,6,7-tetrahydro-9-nitro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]amino]carbonyl]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215105-61-6 HCAPLUS
CN Benzamide, 2-amino-N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 215105-62-7 HCAPLUS
CN 4-Pyridinecarboxamide, 3-(acetylamino)-N-[(3R)-3,4,6,7-tetrahydro-9-nitro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 24 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:682112 HCAPLUS Full-text
DOCUMENT NUMBER: 129:310888

ORIGINAL REFERENCE NO.: 129:63297a,63300a
TITLE: Anti-inflammatory medicament containing farnesyl protein transferase inhibitors
INVENTOR(S): Semple, Graeme; Junien, Jean-Louis; Kendrick, David Alan
PATENT ASSIGNEE(S): Ferring B.V., Neth.
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9843629	A1	19981008	WO 1998-GB976	19980402 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
GB 2323783	A	19981007	GB 1997-6652	19970402 <--
AU 9868474	A	19981022	AU 1998-68474	19980402 <--
PRIORITY APPLN. INFO.:			GB 1997-6652 A	19970402 <--
			WO 1998-GB976 W	19980402 <--

AB Medicament containing inhibitors of farnesyl protein transferase are claimed for the treatment of an inflammatory pathol. condition or the associated pain. Thus, 1-(2-amino-3-mercaptopropyl)-2-butyl-4-(1- naphthoyl)piperazine, at a concentration of 1 μM, inhibited the proliferation of cultured human T-lymphocytes by 72%.

IT 149786-88-9 184687-64-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory medicament containing farnesyl protein transferase inhibitors)

RN 149786-88-9 HCAPLUS
CN L-Methionine, L-cysteinyl-2,3-dihydro-3-(methylamino)-2-oxo-5-phenyl-1H-1,4-benzodiazepine-1-acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184687-64-7 HCAPLUS
CN L-Methionine, L-cysteinyl-2,3-dihydro-3-(methylamino)-2-oxo-5-phenyl-1H-

1,4-benzodiazepine-1-acetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:394349 HCAPLUS Full-text
DOCUMENT NUMBER: 129:54608
ORIGINAL REFERENCE NO.: 129:11385a,11388a
TITLE: Inhibitors of interleukin-1β converting enzyme
INVENTOR(S): Golec, Julian M. C.; Lauffer, David J.; Livingston, David J.; Mullican, Michael D.; Murcko, Mark A.; Nyce, Philip L.; Robidoux, Andrea L. C.; Wannamaker, Marion W.
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA; Golec, Julian M. C.; Lauffer, David J.; Livingston, David J.; Mullican, Michael D.; Murcko, Mark A.; Nyce, Philip L.; Robidoux, Andrea L. C.; Wannamaker, Marion W.
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824805	A1	19980611	WO 1997-US22289	19971205 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2274249	A1	19980611	CA 1997-2274249	19971205 <--
AU 9858960	A	19980629	AU 1998-58960	19971205 <--
EP 944645	A1	19990929	EP 1997-954531	19971205 <--
EP 944645	B1	20050309		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001505883	T	20010508	JP 1998-525818	19971205 <--
AT 290545	T	20050315	AT 1997-954531	19971205 <--
PT 944645	T	20050630	PT 1997-954531	19971205 <--

ES 2239788	T3	20051001	ES 1997-954531		19971205 <--
US 6329365	B1	20011211	US 1999-326495		19990604 <--
US 20030069228	A1	20030410	US 2001-35850		20011023 <--
US 6573259	B2	20030603			
US 20040048855	A1	20040311	US 2003-424576		20030425 <--
US 6974809	B2	20051213			
PRIORITY APPLN. INFO.:			US 1996-32792P	P	19961206 <--
			US 1997-42660P	P	19970404 <--
			US 1997-53001P	P	19970626 <--
			WO 1997-US22289	W	19971205 <--
			US 1999-326495	A3	19990604 <--
			US 2001-35850	A3	20011023 <--

OTHER SOURCE(S): MARPAT 129:54608

GI



I

AB The present invention relates to novel classes of compds. I [RC:CR is an optionally substituted aryl or heteroaryl ring; R1 = aryl, heteroaryl, alkylaryl, alkylheteroaryl; R2 = bond, CO, COCO, SO2, OCO, NHCO, NHSO2, NHCOCO, CH:CHCO, OCH2CO, NHCH2CO, etc.; R3 = aryl, heteroaryl, cycloalkyl, alkyl, dialkylamino; Y = R5CO(CH2)mCH2CH(COR6) or related lactones or semicarbazones, where R5 = OH, alkoxy, NHOH, etc.; R6 = H, HOCH2, aroyloxymethyl, etc.; m = 0 or 1] which were prepared as inhibitors of interleukin-1β converting enzyme. (ICE). Thus, (3S)-3-[3(R,S)-[(benzyloxycarbonyl)amino]-1,3-dihydro-2-oxo-5-phenyl-2H- 1,4-benzodiazepin-1-acetylamino]-4-oxobutyric acid, prepared from 3(R,S)-[(benzyloxycarbonyl)amino]-1,3-dihydro-2-oxo-5-phenyl-2H-1,4- benzodiazepin-1-acetic acid and (3S)-3-(1-fluorenylmethoxycarbonylamino)-4- oxobutyric acid tert-Bu ester semicarbazone, showed ICE inhibition constant Ki = 650 nM and IC50 = 20,000 nM.

IT 172968-04-6P 208758-94-5P 208758-95-6P
208758-96-7P 208758-97-8P 208758-98-9P
208758-99-0P 208759-00-6P 208759-01-7P
208759-02-8P 208759-03-9P 208759-04-0P
208759-05-1P 208759-06-2P 208759-07-3P
208759-09-5P 208759-11-9P 208759-13-1P
208759-15-3P 208759-17-5P 208759-19-7P
208759-21-1P 208759-24-4P 208759-26-6P
208759-28-8P 208759-30-2P 208759-32-4P
208759-34-6P 208759-39-1P 208759-40-4P
208759-41-5P 208759-42-6P 208759-43-7P
208759-44-8P 208759-45-9P 208759-46-0P
208759-47-1P 208759-48-2P 208759-49-3P
208759-50-6P 208759-51-7P 208759-52-8P
208759-53-9P 208759-54-0P 208759-55-1P
208759-56-2P 208759-57-3P 208759-58-4P
208759-59-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitors of interleukin-1β converting enzyme)

RN 172968-04-6 HCAPLUS
CN 1H-1,4-Benzodiazepine-1-acetic acid, 2,3-dihydro-2-oxo-5-phenyl-3-[[(phenylmethoxy)carbonyl]amino]- (CA INDEX NAME)



RN 208758-94-5 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-2-oxo-5-phenyl-3-[[(phenylmethoxy)carbonyl]amino]-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208758-95-6 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[(3,5-dichloro-4-methoxybenzoyl)amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208758-96-7 HCAPLUS
CN Butanoic acid, 3-[[2-[3-(benzoylamino)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208758-97-8 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[4-(acetylamino)benzoyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208758-98-9 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[4-(acetylamino)-3-chlorobenzoyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208758-99-0 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-3-[(4-methoxy-3,5-dimethylbenzoyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-00-6 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[(4-amino-3,5-dichlorobenzoyl)amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-01-7 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-3-[(4-methoxybenzoyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-02-8 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[4-(dimethylamino)benzoyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-03-9 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-3-[(2-methoxybenzoyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-04-0 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-3-[(1-isoquinolinylcarbonyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-05-1 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[(1,3-benzodioxol-5-ylcarbonyl)amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-06-2 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-2-oxo-5-phenyl-3-[(2-phenylacetyl)amino]-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-07-3 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[(cyclohexylcarbonyl)amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-09-5 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-11-9 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-2-oxo-5-phenyl-3-[[(phenylamino)carbonyl]amino]-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-13-1 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-2-oxo-5-phenyl-3-[[[(phenylmethyl)amino]carbonyl]amino]-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-15-3 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[(4-amino-3-chlorobenzoyl)amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-17-5 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-3-[(4-hydroxy-3,5-dimethylbenzoyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-19-7 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-3-[(4-hydroxybenzoyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-21-1 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[(3,5-dichloro-4-hydroxybenzoyl)amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-24-4 HCAPLUS
CN Benzoic acid, 3,5-dichloro-4-hydroxy-, 4-[[[1-[2-[[(1S)-2-carboxy-1-formylethyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]-2,6-dichlorophenyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-26-6 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-2-oxo-5-phenyl-3-[(phenylsulfonyl)amino]-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-28-8 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-2-oxo-3-[(2-oxo-2-phenylacetyl)amino]-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-30-2 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-3-[(1-naphthalenylcarbonyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-32-4 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-3-[(2-naphthalenylcarbonyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-38-0 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-3-[[(4-methoxyphenyl)sulfonyl]amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-39-1 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[(5-chloro-2-methoxyphenyl)sulfonyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-40-4 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-3-[(1-naphthalenylsulfonyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-41-5 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-3-[(2-naphthalenylsulfonyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-42-6 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[[2-(acetylamino)-4-methyl-5-thiazolyl]sulfonyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-43-7 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[(2,6-dichlorophenyl)sulfonyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-44-8 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-2-oxo-5-phenyl-3-[[(phenylmethyl)sulfonyl]amino]-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-45-9 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[(2,5-dimethoxyphenyl)sulfonyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-46-0 HCAPLUS
CN Butanoic acid, 3-[[[3-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 208759-47-1 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-2-oxo-3-[[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-48-2 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-2-oxo-3-[[2-oxo-2-(2-thienyl)acetyl]amino]-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-49-3 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[2-(2,6-dimethoxyphenyl)-2-oxoacetyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-50-6 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[(3-chloro-4-hydroxybenzoyl)amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-51-7 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[[4-(acetylamino)phenyl]sulfonyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-52-8 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[[4-(acetylamino)-3-chlorophenyl]sulfonyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-53-9 HCAPLUS
CN Butanoic acid, 3-[[2-[2,3-dihydro-2-oxo-5-phenyl-3-[(8-quinolinylsulfonyl)amino]-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-54-0 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-55-1 HCAPLUS
CN Benzoic acid, 4-[[[1-[2-[[(1S)-2-carboxy-1-formylethyl]amino]-2-oxoethyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-56-2 HCAPLUS
CN Butanoic acid, 3-[[2-[3-[[(3,5-dichloro-4-hydroxyphenyl)sulfonyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-57-3 HCAPLUS
CN 1H-1,4-Benzodiazepine-1-acetamide, 7-amino-2,3-dihydro-3-[(4-hydroxy-3,5-dimethylbenzoyl)amino]-2-oxo-5-phenyl-N-[(3S)-tetrahydro-5-oxo-2-(phenylmethoxy)-3-furanyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-58-4 HCAPLUS
CN Butanoic acid, 3-[[2-[7-(acetylamino)-2,3-dihydro-3-[(4-hydroxy-3,5-dimethylbenzoyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 208759-59-5 HCAPLUS
CN Butanoic acid, 3-[[2-[7-amino-2,3-dihydro-3-[(4-hydroxy-3,5-dimethylbenzoyl)amino]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-

yl]acetyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 108895-98-3 204322-85-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(inhibitors of interleukin-1β converting enzyme)
RN 108895-98-3 HCAPLUS
CN Carbamic acid, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (CA INDEX NAME)



RN 204322-85-0 HCAPLUS
CN 1H-1,4-Benzodiazepine-1-acetic acid, 3-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2,3-dihydro-2-oxo-5-phenyl- (CA INDEX NAME)



IT 208759-33-5DP, resin-bound 208759-34-6DP, resin-bound 208759-35-7DP, resin-bound 208759-36-8DP, resin-bound 208759-37-9P 208759-60-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(inhibitors of interleukin-1β converting enzyme)

RN 208759-33-5 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[[2-[(2S)-4-(1,1-dimethylethoxy)-2-[[2-[3-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-oxobutylidene]hydrazinyl]carbonyl]amino]methyl]-, trans- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 208759-34-6 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[[2-[(2S)-2-[[2-(3-amino-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl)acetyl]amino]-4-(1,1-dimethylethoxy)-4-oxobutylidene]hydrazinyl]carbonyl]amino]methyl]-, trans- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 208759-35-7 HCAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[[2-[(2S)-2-[[2-[3-[(3,5-dichloro-4-methoxybenzoyl)amino]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-(1,1-dimethylethoxy)-4-oxobutylidene]hydrazinyl]carbonyl]amino]methyl]-, trans- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



RN 208759-36-8 HCAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[[2-[(2S)-2-[[2-[3-(benzoylamino)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-4-(1,1-dimethylethoxy)-4-oxobutylidene]hydrazinyl]carbonyl]amino]methyl]-, trans- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 208759-37-9 HCAPLUS
CN 1H-1,4-Benzodiazepine-1-acetic acid, 2,3-dihydro-2-oxo-5-phenyl-3-[[(phenylmethoxy)carbonyl]amino]-, methyl

ester (CA INDEX NAME)



RN 208759-60-8 HCAPLUS
CN Butanoic acid, 4-[2-(aminocarbonyl)hydrazinylidene]-3-[[2-[2,3-dihydro-2-oxo-5-phenyl-3-[[(phenylmethoxy)carbonyl]amino]-1H-1,4-benzodiazepin-1-yl]acetyl]amino]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 26 OF 26 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:452009 HCAPLUS Full-text
DOCUMENT NUMBER: 125:114721
ORIGINAL REFERENCE NO.: 125:21539a,21542a
TITLE: Diazepino-indoles as phosphodiesterase IV inhibitors.
INVENTOR(S): Pascal, Yves; Moodley, Indres; Calvet, Alain; Junien, Jean-Louis; Dahl, Svein G.
PATENT ASSIGNEE(S): Institut De Recherche Jouveinal, Fr.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9611690	A1	19960425	WO 1995-FR1354	19951013 <--
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2725719	A1	19960419	FR 1994-12282	19941014 <--
FR 2725719	B1	19961206		

US 5852190	A	19981222	US 1995-391865	19950222	<--
CA 2200628	A1	19960425	CA 1995-2200628	19951013	<--
AU 9537494	A	19960506	AU 1995-37494	19951013	<--
AU 703773	B2	19990401			
ZA 9508669	A	19970414	ZA 1995-8669	19951013	<--
EP 785789	A1	19970730	EP 1995-935495	19951013	<--
EP 785789	B1	20020911			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
CN 1160352	A	19970924	CN 1995-195634	19951013	<--
CN 1097459	C	20030101			
BR 9509353	A	19971230	BR 1995-9353	19951013	<--
HU 77411	A2	19980428	HU 1997-2065	19951013	<--
JP 10507447	T	19980721	JP 1996-512999	19951013	<--
NZ 294642	A	20010629	NZ 1995-294642	19951013	<--
RU 2174517	C2	20011010	RU 1997-108048	19951013	<--
AT 223720	T	20020915	AT 1995-935495	19951013	<--
SK 282766	B6	20021203	SK 1997-448	19951013	<--
PT 785789	T	20021231	PT 1995-935495	19951013	<--
ES 2181793	T3	20030301	ES 1995-935495	19951013	<--
NO 9701687	A	19970613	NO 1997-1687	19970411	<--
PRIORITY APPLN. INFO.:			FR 1994-12282	A 19941014	<--
			WO 1995-FR1354	W 19951013	<--
OTHER SOURCE(S):		MARPAT 125:114721			

GI



I



II

AB Diazepinoindole derivs. I [R = H, alkyl, or alkoxy; A = mono- to trisubstituted aryl or heteroaryl] and their racemic forms, enantiomers, and pharmaceutically acceptable salts, including novel compds., are useful for treatment of disorders requiring therapy with phosphodiesterase IV (PDE IV) inhibitors. Examples include prepns. of approx. 75 I and 15 precursors, plus a general tablet formulation, and several bioassays of selected compds. For instance, amidation of 3-amino-1-phenyl-6,7-dihydro-3H-[1,4]diazepino[6,7,1-hi]indol-4-one with imidazo[1,2-a]pyridine-2-carboxylic acid, using the reagent PyBrop and Et3N in THF, gave 71% title compound II. In a test for inhibition of guinea pig tracheal PDE IV in vitro, I were approx. 2-3 times as active as rolipram, e.g., 3.7 times in the case of II. Another compound showed no oral toxicity in rats at 100 mg/kg/day, and 2 other compds. showed no emetic effects in dogs at 3 mg/kg i.v.

IT 179024-50-1P 179024-51-2P 179024-53-4P
179024-55-6P 179024-56-7P 179024-58-9P
179024-60-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of diazepinoindoles as phosphodiesterase IV inhibitors)

RN 179024-50-1 HCAPLUS

CN L-Phenylalanine, N-acetyl-, compd. with (R)-3-amino-6,7-dihydro-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 126252-50-4
CMF C17 H15 N3 O

Absolute stereochemistry. Rotation (+).



CM 2

CRN 2018-61-3
CMF C11 H13 N O3

Absolute stereochemistry. Rotation (+).



RN 179024-51-2 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-9-methyl-1-phenyl- (CA INDEX NAME)



RN 179024-53-4 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-3,4-dione, 6,7-dihydro-9-methyl-1-phenyl-, 3-oxime (CA INDEX NAME)



RN 179024-55-6 HCAPLUS
CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, [R-(R*,R*)]-, compd. with (R)-3-amino-6,7-dihydro-9-methyl-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 179024-54-5
CMF C18 H17 N3 O

Absolute stereochemistry. Rotation (+).



CM 2

CRN 32634-66-5
CMF C20 H18 O8

Absolute stereochemistry. Rotation (-).



RN 179024-56-7 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-9-methoxy-1-phenyl- (CA INDEX NAME)



RN 179024-58-9 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine-3,4-dione, 6,7-dihydro-9-methoxy-1-phenyl-, 3-oxime (CA INDEX NAME)



RN 179024-60-3 HCAPLUS
CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, [R-(R*,R*)]-, compd. with (R)-3-amino-6,7-dihydro-9-methoxy-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 179024-59-0
CMF C18 H17 N3 O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 32634-66-5
CMF C20 H18 O8

Absolute stereochemistry. Rotation (-).



IT 179023-97-3P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diazepinoindoles as phosphodiesterase IV inhibitors)
RN 179023-97-3 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 179024-04-5P 179024-48-7P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diazepinoindoles as phosphodiesterase IV inhibitors)
RN 179024-04-5 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-48-7 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 179024-24-9P 179024-28-3P 179024-29-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diazepinoindoles as phosphodiesterase IV inhibitors)
RN 179024-24-9 HCAPLUS
CN Benzamide, 2-(acetyloxy)-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-28-3 HCAPLUS
CN Carbamic acid, [4-[[[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]amino]carbonyl]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179024-29-4 HCAPLUS
CN 4-Pyridinecarboxamide, 3-amino-N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 126371-30-0P 179023-76-8P 179023-77-9P
179023-78-0P 179023-79-1P 179023-80-4P
179023-81-5P 179023-82-6P 179023-83-7P
179023-84-8P 179023-85-9P 179023-86-0P
179023-87-1P 179023-88-2P 179023-89-3P
179023-90-6P 179023-91-7P 179023-92-8P
179023-93-9P 179023-94-0P 179023-95-1P
179023-96-2P 179023-98-4P 179024-00-1P
179024-01-2P 179024-02-3P 179024-03-4P
179024-05-6P 179024-06-7P 179024-07-8P
179024-08-9P 179024-09-0P 179024-10-3P

179024-11-4P 179024-12-5P 179024-13-6P
179024-14-7P 179024-15-8P 179024-16-9P
179024-17-0P 179024-18-1P 179024-19-2P
179024-20-5P 179024-21-6P 179024-22-7P
179024-23-8P 179024-25-0P 179024-26-1P
179024-27-2P 179024-30-7P 179024-31-8P
179024-32-9P 179024-33-0P 179024-34-1P
179024-35-2P 179024-36-3P 179024-37-4P
179024-38-5P 179024-39-6P 179024-40-9P
179024-41-0P 179024-42-1P 179024-43-2P
179024-44-3P 179024-45-4P 179024-46-5P
179024-47-6P 179024-49-8P 179236-85-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diazepinoindoles as phosphodiesterase IV inhibitors)

RN 126371-30-0 HCAPLUS
CN 1H-Indole-2-carboxamide, N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 179023-76-8 HCAPLUS
CN 5-Pyrimidinecarboxamide, 2-chloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 179023-77-9 HCAPLUS
CN Imidazo[1,2-a]pyridine-2-carboxamide, N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)- (CA INDEX NAME)



RN 179023-78-0 HCAPLUS
CN Benzamide, 2-fluoro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-79-1 HCAPLUS
CN Benzamide, 3-fluoro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-80-4 HCAPLUS
CN Benzamide, 4-fluoro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-81-5 HCAPLUS
CN Benzamide, 2-chloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-82-6 HCAPLUS
CN Benzamide, 3-chloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-83-7 HCAPLUS
CN Benzamide, 2-iodo-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-84-8 HCAPLUS
CN Benzamide, 3-chloro-4-fluoro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-85-9 HCAPLUS
CN Benzamide, 3,4-dichloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-86-0 HCAPLUS
CN Benzamide, 2-methyl-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-87-1 HCAPLUS
CN Benzamide, 2-methoxy-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-88-2 HCAPLUS
CN Benzamide, 3-methoxy-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-89-3 HCAPLUS
CN Benzamide, 4-methoxy-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-90-6 HCAPLUS
CN Benzamide, 5-chloro-2-methoxy-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179023-91-7 HCAPLUS
CN Benzamide, 4-(acetylamino)-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-92-8 HCAPLUS
CN 2-Pyridinecarboxamide, N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-93-9 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-94-0 HCAPLUS
CN 3-Quinolinecarboxamide, N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-95-1 HCAPLUS
CN 6-Quinolinecarboxamide, N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179023-96-2 HCAPLUS
CN 4-Quinolinecarboxamide, 2-methyl-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179023-98-4 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-00-1 HCAPLUS
CN Isoquinolinium, 2-methyl-3-[[(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodizepin-3-yl)amino]carbonyl]-, (R)-, fluorosulfate (9CI) (CA INDEX NAME)

CM 1

CRN 179023-99-5
CMF C28 H23 N4 O2

Absolute stereochemistry.



CM 2

CRN 15181-47-2
CMF F O3 S

RN 179024-01-2 HCAPLUS
CN Imidazo[1,2-a]pyrimidine-2-carboxamide, N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (-)- (CA INDEX NAME)

Rotation (-).



RN 179024-02-3 HCAPLUS
CN Pyrazolo[5,1-c][1,2,4]triazine-3-carboxamide, 4,7-dimethyl-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-03-4 HCAPLUS
CN 3-Quinolinecarboxamide, N-(3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179024-05-6 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-(3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)- (CA INDEX NAME)



RN 179024-06-7 HCAPLUS
CN Benzamide, 3-chloro-N-(3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-07-8 HCAPLUS

CN Benzamide, 4-chloro-N-[(3R)-3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-08-9 HCAPLUS
CN 4-Pyridinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-09-0 HCAPLUS
CN 3-Quinolinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-10-3 HCAPLUS
CN 6-Quinolinecarboxamide, N-(3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-11-4 HCAPLUS
CN 3-Isoquinolinecarboxamide, N-[(3R)-3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-12-5 HCAPLUS
CN Pyrazolo[5,1-c][1,2,4]triazine-3-carboxamide, 4,7-dimethyl-N-[(3R)-3,4,6,7-tetrahydro-9-methoxy-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-13-6 HCAPLUS
CN Benzamide, 2,4-difluoro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-14-7 HCAPLUS
CN Benzamide, 2,5-difluoro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-15-8 HCAPLUS
CN Benzamide, 3,4-difluoro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-16-9 HCAPLUS
CN Benzamide, 3,5-difluoro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-17-0 HCAPLUS
CN Benzamide, 2,4-dichloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-18-1 HCAPLUS
CN Benzamide, 3,5-dichloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-19-2 HCAPLUS
CN Benzamide, N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-3,5-bis(trifluoromethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-20-5 HCAPLUS
CN Benzamide, 3,4-dimethoxy-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-21-6 HCAPLUS
CN Benzamide, 3-chloro-4-methoxy-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-22-7 HCAPLUS
CN Benzamide, 4-amino-3,5-dichloro-N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-23-8 HCAPLUS
CN Benzamide, 2-(acetylamino)-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-25-0 HCAPLUS
CN Benzamide, 2-hydroxy-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, monopotassium salt, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-26-1 HCAPLUS
CN 3-Pyridinecarboxamide, 5,6-dichloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-27-2 HCAPLUS
CN 4-Pyridinecarboxamide, 3,5-dichloro-N-[(3R)-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-30-7 HCAPLUS
CN 4-Pyridinecarboxamide, 3-(acetylamino)-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179024-31-8 HCAPLUS
CN 4-Pyridinecarboxamide, 3-[(cyclopropylcarbonyl)amino]-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179024-32-9 HCAPLUS
CN Pyrazinecarboxamide, N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-33-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-34-1 HCAPLUS
CN 3-Quinolinecarboxamide, 4-chloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179024-35-2 HCAPLUS
CN 3-Quinolinecarboxamide, 4-chloro-6-fluoro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-36-3 HCAPLUS
CN 3-Quinolinecarboxamide, 4,6-dichloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-37-4 HCAPLUS
CN 3-Quinolinecarboxamide, 4,8-dichloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-38-5 HCAPLUS
CN 3-Quinolinecarboxamide, 6-bromo-4-chloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-39-6 HCAPLUS
CN 3-Quinolinecarboxamide, 4-chloro-6-methyl-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-40-9 HCAPLUS
CN 3-Quinolinecarboxamide, 4-chloro-8-methyl-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-41-0 HCAPLUS
CN 3-Quinolinecarboxamide, 4-chloro-6-methoxy-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-42-1 HCAPLUS
CN 3-Quinolinecarboxamide, 4-chloro-8-methoxy-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-43-2 HCAPLUS
CN 3-Quinolinecarboxamide, 4-chloro-5,7-dimethyl-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-44-3 HCAPLUS
CN 3-Quinolinecarboxamide, 4-chloro-5,8-dimethyl-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-45-4 HCAPLUS
CN 3-Quinolinecarboxamide, 4-chloro-6,8-dimethyl-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-46-5 HCAPLUS
CN 3-Quinolinecarboxamide, 4-chloro-7,8-dimethyl-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-47-6 HCAPLUS
CN Benzamide, 2-methoxy-N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-49-8 HCAPLUS
CN Pyrazolo[5,1-c][1,2,4]triazine-3-carboxamide, 4,7-dimethyl-N-[(3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179236-85-2 HCAPLUS
CN Benzamide, 3,4,5-trimethoxy-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 126252-50-4P 179024-54-5P 179024-59-0P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diazepinoindoles as phosphodiesterase IV inhibitors)
RN 126252-50-4 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-1-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-54-5 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one, 3-amino-6,7-dihydro-9-methyl-1-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 179024-59-0 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one,
3-amino-6,7-dihydro-9-methoxy-1-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 126149-54-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of diazepinoindoles as phosphodiesterase IV inhibitors)
RN 126149-54-0 HCAPLUS
CN Pyrrolo[3,2,1-jk][1,4]benzodiazepin-4(3H)-one,
3-amino-6,7-dihydro-1-phenyl- (CA INDEX NAME)



SEARCH HISTORY

```
=> d his ful

     (FILE 'HOME' ENTERED AT 16:37:53 ON 22 OCT 2008)

     FILE 'HCAPLUS' ENTERED AT 16:40:23 ON 22 OCT 2008
                E DOWDELL VERITY/AU
L1             8 SEA ABB=ON  ("DOWDELL VERITY"/AU OR "DOWDELL VERITY C L"/AU)
                E KELSEY RICHARD/AU
L2            13 SEA ABB=ON  ("KELSEY RICHARD"/AU OR "KELSEY RICHARD D"/AU OR
                "KELSEY RICHARD DAVID"/AU)
                E CARTER MALOLM/AU
                E CARTER MALCOLM/AU
                E ALBER DAGMAR/AU
L3            71 SEA ABB=ON  ("ALBER D"/AU OR "ALBER D G"/AU OR "ALBER DAGMAR"/A
                U)
                E HENDERSON ELISA/AU
L4            14 SEA ABB=ON  ("HENDERSON ELISA"/AU OR "HENDERSON ELISA A"/AU OR
                "HENDERSON ELISA ANN"/AU)
                E HENDERSON ELISA/AU
L5             6 SEA ABB=ON  "HENDERSON ELISA"/AU
L6             3 SEA ABB=ON  L1 AND L2 AND L3 AND L4 AND L5
                SELECT RN L6 2-3

     FILE 'REGISTRY' ENTERED AT 16:42:03 ON 22 OCT 2008
L7           341 SEA ABB=ON  (406940-52-1/BI OR 406941-75-1/BI OR 406942-68-5/BI
                 OR 406943-07-5/BI OR 406944-37-4/BI OR 543700-68-1/BI OR
                682754-93-4/BI OR 682755-55-1/BI OR 682755-63-1/BI OR 682755-73
                -3/BI OR 682755-77-7/BI OR 74733-75-8/BI OR 865724-48-7/BI OR
                865724-49-8/BI OR 865788-63-2/BI OR 1019852-79-9/BI OR
                1019852-94-8/BI OR 103343-47-1/BI OR 103373-17-7/BI OR
                103373-21-3/BI OR 108895-98-3/BI OR 109-01-3/BI OR 115029-23-7/
                BI OR 115029-24-8/BI OR 116842-74-1/BI OR 119082-97-2/BI OR
                119506-69-3/BI OR 120800-52-4/BI OR 123-90-0/BI OR 150964-48-0/
                BI OR 1583-58-0/BI OR 164149-28-4/BI OR 168162-29-6/BI OR
                175153-55-6/BI OR 190660-95-8/BI OR 19788-35-3/BI OR 206115-23-
                3/BI OR 21278-86-4/BI OR 2148-56-3/BI OR 216959-92-1/BI OR
                2305-36-4/BI OR 2457-76-3/BI OR 2528-00-9/BI OR 253135-95-4/BI
                OR 26095-36-3/BI OR 299181-75-2/BI OR 301353-36-6/BI OR
                317846-22-3/BI OR 337508-64-2/BI OR 34040-63-6/BI OR 34776-79-9
                /BI OR 3680-02-2/BI OR 368870-46-6/BI OR 368870-47-7/BI OR
                368870-49-9/BI OR 368870-50-2/BI OR 380339-63-9/BI OR 380605-23
                -2/BI OR 39067-29-3/BI OR 39093-93-1/BI OR 400750-49-4/BI OR
                400878-25-3/BI OR 4025-64-3/BI OR 4173-63-1/BI OR 42106-48-9/BI
                 OR 423768-54-1/BI OR 4389-45-1/BI OR 4389-50-8/BI OR 446-08-2/
                BI OR 478628-20-5/BI OR 53020-07-8/BI OR 5326-23-8/BI OR
                5345-47-1/BI OR 5470-18-8/BI OR 59377-19-4/BI OR 6338-41-6/BI
                OR 635-21-2/BI OR 676127-99-4/BI OR 676128-01-1/BI OR 676128-02
                -2/BI OR 676128-03-3/BI OR 676128-04-4/BI OR 676128-05-5/BI OR
                676128-06-6/BI OR 676128-07-7/BI OR 676128-08-8/BI OR 676128-09
                -9/BI OR 676128-10-2/BI OR 676128-11-3/BI OR 676128-12-4/BI OR
                676128-13-5/BI OR 676128-14-6/BI OR 676128-15-7/BI OR 676128-16
                -8/BI OR 676128-17-9/BI OR 676128-18-0/BI OR 676128-19-1/BI OR
                676128-20-4/BI OR 676128-21-5/BI OR 676128-22-6/BI OR 676128-23
                -7/BI OR 676128-24-8/BI OR 676128-25-9/BI OR 676128-26-0/BI OR
                676128-27-1/BI OR 676128-28-2/BI OR 676128-29-3/BI OR 676128-30
                -6/BI OR 676128-31-7/BI OR 676128-32-8/BI OR 676128-33-9/BI OR
                676128-34-0/BI OR 676128-35-1/BI OR 676128-36-2/BI OR 676128-37
```

-3/BI OR 67

FILE 'HCAPLUS' ENTERED AT 16:42:38 ON 22 OCT 2008
L8 2 SEA ABB=ON L6 AND L7

FILE 'REGISTRY' ENTERED AT 16:43:49 ON 22 OCT 2008
L9 STR
L10 50 SEA SSS SAM L9
L11 8863 SEA SSS FUL L9

FILE 'HCAPLUS' ENTERED AT 16:45:21 ON 22 OCT 2008
L12 962 SEA ABB=ON L11
L13 46 SEA ABB=ON L12 AND (RSV+ALL OR ?ASTHMA? OR (?CHRONIC?(W)?OBSTR ?(W)?PULM? OR ?LUNG?)(W)?DISEAS?)

FILE 'REGISTRY' ENTERED AT 16:48:38 ON 22 OCT 2008
L14 STRUCTURE 865471-08-5
L15 0 SEA SSS SAM L14
L16 1 SEA ABB=ON 865471-08-5/RN

FILE 'HCAPLUS' ENTERED AT 16:49:22 ON 22 OCT 2008
L17 3 SEA ABB=ON L16
L18 46 SEA ABB=ON L13 OR L17
L19 23 SEA ABB=ON L18 AND (PRD<20040319 OR PD<20040319)
L20 26 SEA ABB=ON L17 OR L19

FILE HOME

FILE HCAPLUS

FILE COVERS 1907 - 22 Oct 2008 VOL 149 ISS 17
FILE LAST UPDATED: 21 Oct 2008 (20081021/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 OCT 2008 HIGHEST RN 1064205-90-8
DICTIONARY FILE UPDATES: 21 OCT 2008 HIGHEST RN 1064205-90-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html